powerpoint presentation nsv 2018 070618 v3.pdf · nsv 2013: palacio de congresos, granada, spain...

NSV2018

June 17-22, 2018

Verona

General Information

MEETING ORGANIZERS

USEFUL NUMBERS

Dominique Garcin: University of Geneva, SwitzerlandGrazia Cusi: University of Siena, Siena, Italy

Wendy Barclay: Imperial College, London, UKPaul Duprex: Boston University, Boston, USA

Sean Whelan: Harvard Medical School, Boston, USA

Emergency: 118 Local Police: 112 / 113 Ambulance: 118

Administrative Secretariat:

MCI Geneva9, rue Pré-Bouvier1242 Satigny / GenevaSwitzerlandOnsite Phone: +41 765714224Email: nsv.reg@mci-group.com

The organizers gratefully acknowledge David Zenaty and Keith Ketterer, Harvard Medical School for administrative and website support

Local Secretariat:

IantraPiazza Donatori di Sangue 537124 VeronaItaly

History of NSV

The first meeting, entitled “The biology of large RNA viruses” was organized byRichard D. Barry and Brian W. J. Mahy in 1969, Cambridge England. A symposiumvolume was published following this congress and includes presentations onnegative-strand RNA viruses and retroviruses. The meeting predated thediscovery of reverse transcriptase and the recognition that the negative-strandRNA viruses contain an RNA polymerase within the virion.

This is the premier meeting in the field of negative strand RNA viruses. Theconference is limited in size to approximately 400 participants, with presentationsthat cover all aspects of the fundamental biology of negative strand RNA viruses.This is the 17th meeting and we continue in the spirit of previous conferences andthere will be no invited speakers or concurrent sessions.

NSV 1969: Pembroke College, Cambridge, UKNSV 1973: King’s College, Cambridge, UKNSV 1977: King’s College, Cambridge, UKNSV 1980: St. Thomas, Virgin Islands, USANSV 1982: Hilton Head, NC, USANSV 1985: Robinson College, Cambridge, UKNSV 1988: Palais des Congrès, Dinard, FranceNSV 1991: Hibernian Hall, Charleston, SC, USANSV 1994: Hotel Estoril Sol, Estoril, PortugalNSV 1997: Trinity College, Dublin, IrelandNSV 2000: Palais Montcalm, Québec City, CanadaNSV 2003: Palazzo dei Congressi, Pisa, ItalyNSV 2006: Hospederia de Fonseca, Salamanca, SpainNSV 2010: Concertgebouw, Bruges, BelgiumNSV 2013: Palacio de Congresos, Granada, SpainNSV 2015: Università di Siena, Siena, ItalyNSV 2018: Gran Guardia Palace, Verona, Italy

The scientific program is complemented by a vibrant social program designed tofoster interactions among all of the attendees, welcome newcomers to the field,strengthen our community and provide life-long memories.

Future of NSV

The organizing committee would like to encourage you to visit Poster P000 so thatyou can have input on the future of NSV. This poster will remain up throughoutthe meeting and we ask that you visit the poster and talk to the organizers.Among the topics we seek feedback on are:

• Formation of a non-profit organization whose sole objective is the organization of the Negative Strand Virus meeting

• Membership of the non-profit organization• Culture of the meeting• Ensuring access to all members of the community

Image courtesy of Rebekah Dumm and Nick Heaton, Duke University, USA

Verona

Gran Guardia

Romantheater

Juliet’s balcony

piazza Erbe

piazza Bra

In fair Verona, where we lay our scene …

Social Program

WELCOME RECEPTION

The welcome reception will take place on the terrace of the Gran Guardia Palacefrom 19:00-22:00 on Sunday, June 17. Come and see the view of the Arena, meetold and new friends and enjoy some Italian hospitality.

WALKING TOUR OF VERONA

The historic city of Verona was founded in the 1st Century BC. Verona haspreserved a remarkable number of monuments from antiquity, the medieval andRenaissance periods, and represents an outstanding example of a militarystronghold. So splendid is the city that its reputation alone inspired Shakespeareto set two plays here. We will learn about the city’s past as we wander thecharming streets on Monday, June 18.

Social Program

DINNER BY THE LAKE

GALA DINNER

A trip to this region would be incomplete without visiting Lake Garda – the largestlake in Italy. Take time to walk around the picturesque town of Lazise and thenhave an aperitif followed by a buffet at the Dogana Veneta. Buses leave from theGran Guardia at 18:30 on Tuesday, June 19.

The Gala Dinner has been a highlight of the NSV social program since its inception.Join us at beautiful Villa Arvedi – built in the 17th Century – and frescoed by theFrench painter Ludovico Dorigny. Buses leave from the Gran Guardia at 18:45 onThursday, June 21.

Week at a glance

PROGRAM

SUNDAY MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY9

BREAKING&

ENTERING

EXPRESSING&

MULTIPLYING

BUILDING&

ESCAPING

DAMAGING&

SPREADINGEMERGING

&EVOLVING

COFFEE & POSTERSCOFFEE11

SUPPRESSING &

CONQUERING

FIGHTING&

RESPONDINGBREAKING

&ENTERING

BUILDING&

ESCAPING

EMERGING&

EVOLVING12

LUNCH13

LUNCH & POSTERS

SUPPRESSING &

CONQUERING

FIGHTING&

RESPONDING

EXPRESSING&

MULTIPLYING

DAMAGING&

SPREADING15

COFFEE & POSTERS16

SUPPRESSING &

CONQUERING

FIGHTING&

RESPONDINGEXPRESSING&

MULTIPLYING

DAMAGING&

SPREADING

WALKING TOUR LAKE GARDA

DOGANA VENETA FREE EVENING

GALA DINNER

VILLA ARVEDI

19WELCOME RECEPTION

GRANGUARDIA

FREE EVENING21

Sunday June 17

14:00-18:30 Registration:Gran GuardiaPiazza Bra, 137121 Verona

Poster Session One: P000, P230, P001-P123Monday, June 18 and Tuesday June 19

Poster dismantlingTuesday, June 19, at the end of the session

Poster Session Two: P000, P230, P124-P249Wednesday, June 20 and Thursday June 21

Poster dismantlingThursday, June 21, at the end of the session

19:00-22:00 Welcome Reception at Gran Guardia

Session One

Monday June 18

BREAKING AND ENTERING

08:50-09:00 WELCOME TO NSV2018

09:00-09:10 Anne MOSCONA and Kartik CHANDRANChairpersons' remarks

1 09:10-09:30 Silke STERTZ HUMAN LEUCOCYTE ANTIGEN DR (HLA-DR) HOMOLOGS ARE CROSS-SPECIES ENTRY RECEPTORS FOR BAT INFLUENZA VIRUSES.UNIVERSITY OF ZURICH, Zurich, Switzerland

2 09:30-09:50 Roberto CATTANEONECTINS TRANSFER CYTOPLASM BETWEEN CELLS AND CAN SPREAD MEASLES VIRUS TO NEURONSMAYO CLINIC, Rochester, United States

3 09:50-10:00 Donald BENTONSTRUCTURE OF FULL-LENGTH INFLUENZA HAEMAGGLUTININTHE FRANCIS CRICK INSTITUTE, London, United Kingdom

4 10:00-10:10 Aurelie ALBERTINISTRUCTURAL BASIS OF LOW-DENSITY LIPOPROTEIN RECEPTOR RECOGNITION BY VSV GLYCOPROTEINCNRS, GIF SUR YVETTE, France

5 10:10-10:20 Eva MITTLERDELINEATING INTERACTION OF FILOVIRAL GP WITH ITS ENDOSOMAL RECEPTOR NPC1 BY IN SITU PROXIMITY LIGATIONALBERT EINSTEIN COLLEGE OF MEDICINE, New York, United States

6 10:20-10:30 Rohit JANGRAHOST FACTOR REQUIRED FOR IN VIVO PATHOGENICITY OF NEW WORLD HANTAVIRUSESALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States

COFFEE BREAK WITH POSTERS 10:30-11:30

Monday June 18BREAKING AND ENTERING

7 11:30-11:50 Rebecca DUTCHANCHORING THE SPRING: THE ROLE OF TRANSMEMBRANE DOMAIN INTERACTIONS IN VIRAL FUSION PROTEIN FUNCTIONUNIVERSITY OF KENTUCKY, Lexington, United States

8 11:50-12:10 Hector AGUILAR-CARRENO UNCOVERING A NEW PARAMYXOVIRAL ATTACHMENT GLYCOPROTEIN ROLE BEYOND FUSION TRIGGERINGCORNELL UNIVERSITY, Ithaca, United States

9 12:10-12:30 Nicole TISCHLER HANTAVIRUS GC HOMOMERIC DIMER AND TRIMER CONTACTS DIRECT SPIKE DISSOCIATION AND MEMBRANE FUSIONFUNDACIÓN CIENCIA PARA LA VIDA, Santiago, Chile

10 12:30-12:40 Ilona RISSANENANTIGENIC ARRANGEMENT OF THE DYNAMIC HANTAVIRAL SURFACEUNIVERSITY OF HELSINKI, Helsinki, Finland

11 12:40-12:50 Chiara FEDELIRECEPTOR TYROSINE KINASES ARE PROMISING TARGETS IN LASSA VIRUS ANTIVIRAL THERAPYCHUV, Lausanne, Switzerland

LUNCH 12:50-14:20

Session Two

EXPRESSING AND MULTIPLYING

14:20-14:30 Ervin FODOR, Ben HALE and Rachel FEARNSChairpersons' remarks

12 14:30-14:50 Juan REGUERASTRUCTURE AND FUNCTION OF PHENUIVIRIDAE CAP-SNATCHING ENDONUCLEASESINSERM, Marseille, France

13 14:50-15:10 Sean WHELANMECHANISM OF POLYMERASE REGULATION BY A 5’ HOOK LIKE STRUCTURE IN THE GENOMIC RNA OF MACHUPO VIRUS.HARVARD MEDICAL SCHOOL, Boston, United States

14 15:10-15:20 Haitan FANSTRUCTURAL INSIGHTS INTO THE MECHANISMS OF INFLUENZA A VIRUS RNA REPLICATIONUNIVERSITY OF OXFORD, Oxford, United Kingdom

15 15:20-15:30 Akiko MAKINOTRANSLATIONAL REGULATION OF BORNA DISEASE VIRUSKYOTO UNIVERSITY, Kyoto, Japan

16 15:30-15:50 Jianrong LIVIRAL N6-METHYLADENOSINE PROMOTES REPLICATION AND GENE EXPRESSION OF PNEUMOVIRUSESTHE OHIO STATE UNIVERSITY, Columbus, United States

COFFEE BREAK AND POSTERS 15:50-16:50

17 16:50-17:10 Christopher BASLERPROTEOMIC ANALYSIS IDENTIFIES HUMAN E3 UBIQUITIN LIGASE RBBP6 AS A NEGATIVE REGULATOR OF EBOLA VIRUS INFECTIONGEORGIA STATE UNIVERSITY, Atlanta, United States

18 17:10-17:20 Simone BACHADVANCED ANALYSES ON THE ROLE OF VP30 AND RNA STRUCTURES IN EBOLA VIRUS TRANSCRIPTIONPHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany

19 17:20-17:40 Andrew MEHLEREPURPOSING CANONICAL ANTIVIRAL RESPONSES TO PROMOTE TRANSLATION OF INFLUENZA VIRUS MESSENGER RNAsUNIVERSITY OF WISCONSIN MADISON, Madison, United States

20 17:40-17:50 Jason LONGBINDING TO ANP32 IS REQUIRED BUT NOT SUFFICIENT FOR INFLUENZA A VIRUS POLYMERASE ACTIVITYIMPERIAL COLLEGE LONDON, London, United Kingdom

21 17:50-18:10 Anice LOWENINCOMPLETE GENOMES OF INFLUENZA A VIRUS DRIVE ABUNDANT REASSORTMENTEmory University, Atlanta, United States

GUIDED TOURS OF VERONA 18:30

#NSV2018

WALKING TOUR OF VERONA

Guided tours leave from the front of Gran Guardia from 18:30-19:00

Tonight we explore the city and a highlight will be the famous Juliet’s balcony.

• Band-Aids and a Sharpie are in your bag!

• suggested activity see photograph below

• meet someone new and share the results broadly with the #NSV2018community on social media or email them to info@negativestrandvirus.org.

• If you don’t tweet what better time to start … enjoy!

Tuesday June 19

22 09:00-09:20 Rachel FEARNSDIFFERENCES BETWEEN TRANSCRIPTION AND REPLICATION INITIATION MECHANISMS OF THE PNEUMO- AND PARAMYXOVIRIDAEBOSTON UNIVERSITY SCHOOL OF MEDICINE, Boston, United States

23 09:20-09:40 Richard RANDALLNEXT GENERATION SEQUENCING REVEALS NOVEL ASPECTS OF PARAMYXOVIRUS TRANSCRIPTION AND REPLICATION AND THE SWITCH BETWEEN ACUTE AND PERSISTENT INFECTIONS.UNIVERSITY OF ST ANDREWS, St Andrews, United Kingdom

24 09:40-09:50 Louis-Marie BLOYETSTRUCTURE GUIDED TUNING OF VESICULAR STOMATITIS VIRUS RNA DEPENDENT RNA POLYMERASE FIDELITYHARVARD MEDICAL SCHOOL, Boston, United States

25 09:50-10:00 Ryan DONOHUETO V, OR NOT TO V? CYCLIC SELECTION OF GENOMIC QUASISPECIES WITH ALTERNATIVE CODING CAPACITIES IN DUAL-TROPIC MEASLES VIRUSMAYO CLINIC, Rochester, United States

26 10:00-10:20 Chris BROOKEINFLUENZA A VIRUS GENOMIC HETEROGENEITY REGULATES SUPERINFECTION POTENTIAL AND THE CELLULAR RESPONSE TO INFECTIONUNIVERSITY OF ILLINOIS, Urbana, United States

COFFEE AND POSTERS 10:20-11:10

Session Three

SUPPRESSING AND CONQUERING

11:10-11:20: Ryan LANGLOIS, Friedemann WEBER and Gaya AMARASINGHEChairpersons' remarks

27 11:20-11:40 Karl-Klaus CONZELMANNNUCLEAR IMPORT OF THE RABIES VIRUS P PROTEIN IS REQUIRED FOR INHIBITION OF RIG-I-LIKE RECEPTOR-MEDIATED TYPE I INTERFERON INDUCTIONLMU MUNICH, München, Germany

28 11:40-12:00 Stephane BIACCHESINOVIRHABDOVIRUS NV PROTEINS ACT AS ANTAGONISTS OF THE HOST ANTIVIRAL DEFENSEINRA, Jouy en Josas, France

29 12:00-12:20 Daisy LEUNGMECHANISMS OF IMMUNE EVASION BY RSV NON-STRUCTURAL PROTEINSWASHINGTON UNIVERSITY SCHOOL OF MEDICINE, St. Louis, United States

30 12:20-12:30 Raquel MUÑOZ-MORENOA BARCODED LIBRARY UNVEILS NS1-DRIVEN INFLUENZA VIRUS TROPISMICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States

31 12:30-12:40 Cornelius ROHDEMARBURG VIRUS PROTEIN VP30 REGULATES THE IRE1/XBP1-DEPENDENT UNFOLDED PROTEIN RESPONSE TO ENSURE EFFICIENT VIRAL REPLICATIONInstitute of Virology, Philipps-University Marburg, Marburg, Germany

LUNCH AND POSTERS 12:40-13:50

32 13:50-14:10 Alexander BUKREYEVSUBVERSION OF LYMPHOCYTE RESPONSE AND MODULATION OF GENE EXPRESSION AND SIGNALING BY EBOLA VIRUSUniversity of Texas Medical Branch at Galveston, Galveston, United States

33 14:10-14:30 Amelia NIETOEPIGENETIC CONTROL OF INFLUENZA VIRUS MEDIATED BY H3K79 HISTONE METHYLATION: ROLE IN INTERFERON-INDUCED ANTIVIRAL RESPONSECENTRO NACIONAL DE BIOTECNOLOGIA-CSIC, Madrid, Spain

34 14:30-14:50 Marta GAGLIATHE INFLUENZA A VIRUS HOST SHUTOFF RNASE PA-X USURPS HOST mRNA PROCESSING MECHANISMSTUFTS UNIVERSITY SCHOOL OF MEDICINE, Boston, United States

35 14:50-15:00 Linda BRUNOTTETRIM28/KAP1 IS A PKR-CONTROLLED NEGATIVE REGULATOR OF THE INNATE IMMUNE RESPONSE TO HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUSESUNIVERSITY OF MUENSTER, Muenster, Germany

36 15:00-15:10 Béryl MAZEL-SANCHEZH5N1 INFLUENZA A VIRUS PB1-F2 RELIEVES HAX-1-MEDIATED RESTRICTION OF AVIAN VIRUS POLYMERASE PA IN HUMAN LUNG CELLSUNIVERSITY OF GENEVA, Geneva, Switzerland

COFFEE AND POSTER SESSION 15:10-16:00

37 16:00-16:20 Caroline GOUJONIDENTIFICATION OF A NEW INTERFERON-INDUCIBLE PROTEIN INHIBITING ENDOSOME MEDIATED VIRAL ENTRY THROUGH REGULATION OF THE VACUOLAR H+-ATPASEINSTITUT DE RECHERCHE EN INFECTIOLOGIE DE MONTPELLIER (IRIM), CNRS/MONTPELLIER UNIVERSITY, Montpellier, France

38 16:20-16:40 Patrick READINGDEFINING HOST RESTRICTION FACTORS THAT MODULATE RESPIRATORY VIRUS ENTRY AND EXIT FROM INFECTED CELLS.PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY, Melbourne, Australia

39 16:40-16:50 Rui GALAOTRIM25 TARGETS EBOLA VIRUS RIBONUCLEOPROTEIN TO SENSITIZE IT TO ZAP-MEDIATED RESTRICTIONKING'S COLLEGE LONDON, London, United Kingdom

40 16:50-17:00 Florine SCHOLTEINHIBITION OF THE CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS-ENCODED DEUBIQUITINASE BLOCKS VIRAL REPLICATIONCDC, Atlanta, United States

41 17:00-17:10 Carles SOLÀ RIERAHANTAAN VIRUS DOWNREGULATES CELL SURFACE EXPRESSION OF DEATH RECEPTOR 5 VIA THE 26S PROTEASOME PATHWAY AND INHIBITS TRAIL-MEDIATED INDUCTION OF APOPTOSISKAROLINSKA INSTITUTET, Stockholm, Sweden

42 17:10-17:20 Elizabeth FAYREPLICATION HETEROGENEITY DRIVES DISTINCT CELLULAR RESPONSES TO INFLUENZA A INFECTION IN VIVOUNIVERSITY OF MINNESOTA, Minneapolis, United States

REMOVE SESSION ONE POSTERSUNREMOVED POSTERS AFTER 17.45 WILL BE DISCARDED!

SOCIAL PROGRAM VISIT TO DOGANA VENETA

BUSES DEPART GRAN GUARDIA 18:30-19:00

RETURN FROM 22:00

Lake Garda

DOGANA VENETA

Buses leave from the front of Gran Guardia at 18:30-19:00

Tonight we visit the lakeside village of Lazise and the “Dogana Veneta” (Customshouse of Veneto) an elegant building built in 1300 from which Venezia controlledthe trades on the Lake Garda for centuries.

Buses return to Verona from 22:00-22:30

Session Four

Wednesday June 20

BUILDING AND ESCAPING

09:00-09:10 Andrea MAISNER and Richard COMPANSChairpersons' remarks

43 09:10-09:30 Edward HUTCHINSONMOLECULAR ANATOMY OF THE INFLUENZA VIRIONMRC-UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH, Glasgow, United Kingdom

44 09:30-09:50 Rob RUIGROKASSEMBLY AND STRUCTURE OF MEASLES VIRUS NUCLEOCAPSID PARTICLESIBS, Grenoble, France

45 09:50-10:00 Masahiro NAKANOULTRASTRUCTURE OF THE INFLUENZA VIRUS RIBONUCLEOPROTEIN COMPLEXES PRODUCING VIRAL RNAsKYOTO UNIVERSITY, Kyoto, Japan

46 10:00-10:20 Yves GAUDINNEGRI BODIES ARE VIRAL FACTORIES WITH PROPERTIES OF LIQUID ORGANELLESINSTITUT DE BIOLOGIE INTÉGRATIVE DE LA CELLULE, CNRS, Gif sur YvetteFrance

47 10:20-10:30 Emily BRUCENEW TECHNIQUES TO VISUALIZE THE MAMMARENAVIRUS (LCMV) LIFE CYCLE REVEAL A RAB5C-POSITIVE COMPARTMENT AS A POTENTIAL SITE FOR GENOME REPLICATION AND VIRAL PARTICLE PRE-ASSEMBLYUNIVERSITY OF VERMONT, BURLINGTON, United States

COFFEE AND POSTER SESSION 10:30-11:30

Wednesday June 19BUILDING AND ESCAPING

48 11:30-11:50 Jason BOTTENKEY LCMV-HOST INTERACTIONS REQUIRED FOR DEFECTIVE INTERFERING PARTICLE PRODUCTION AND THE HIGHLY DYNAMIC STATE OF VIRAL REPLICATION AND TRANSCRIPTION DURING PERSISTENCE.University of Vermont, Burlington, United States

49 11:50-12:00 Verena TE KAMPRESTRICTED INTRANEURONAL TRANSPORT OF FIELD RABIES VIRUS GLYCOPROTEINFRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany

50 12:00-12:20 Jacco BOONNUCLEOTIDE RESOLUTION MAPPING OF INFLUENZA A VIRUS NUCLEOPROTEIN-RNA INTERACTIONS REVEALS THE LANDSCAPE OF VIRAL RNA FEATURES REQUIRED FOR REPLICATIONWASHINGTON UNIVERSITY, Saint Louis, United States

51 12:20-12:30 Naoki TAKIZAWAFINE MAPPING OF INFLUENZA A VIRUS INTRA AND INTERSEGMENT RNA INTERACTIONSINSTITUTE OF MICROBIAL CHEMISTRY (BIKAKEN), Tokyo, Japan

52 12:30-12:50 Seema LAKDAWALAVISUALIZING THE INTRACELLULAR ASSEMBLY OF INFLUENZA VIRAL RNA USING CONFOCAL AND LIGHT SHEET LIVE CELL MICROSCOPEUNIVERSITY OF PITTSBURGH, Pittsburgh, United States

Session Five

DAMAGING AND SPREADING

14:20-14:30 Anthony GRIFFITHS, Sandra DIEDERICH and Diane GRIFFINChairpersons' remarks

53 14:30-14:50 Charles RUSSELLHA STABILITY GOVERNS INFLUENZA A VIRUS REPLICATION, VIRULENCE, HOST RANGE, AND PANDEMIC POTENTIALST. JUDE CHILDREN'S RESEARCH HOSPITAL, MEMPHIS, TN

54 14:50-15:10 Stacey SCHULTZ-CHERRYIMPACT OF OBESITY ON INFLUENZA VIRUS; PATHOGENESIS, VIRAL POPULATIONS AND TRANSMISSIONST JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, United States

55 15:10-15:30 Paul DUPREXMULTIROUTE MORBILLIVIRUS ENTRY: DISEASE INFORMS VACCINE DELIVERYBoston University School of Medicine, Boston, United States

56 15:30-15:40 Daniel SCHNEPFINTERFERON LAMBDA PREVENTS THE SPREAD OF RESPIRATORY VIRUSES FROM THE UPPER RESPIRATORY TRACT TO THE LUNGS AND RESTRICTS VIRUS TRANSMISSION IN MICEMEDICAL CENTER UNIVERSITY OF FREIBURG. Freiburg im Breisgau, Germany

57 15:40-15:50 Judith OYMANSBREACHING THE OVINE PLACENTAL BARRIER BY RIFT VALLEY FEVER VIRUS WAGENINGEN BIOVETERINARY RESEARCH, Utrecht, Netherlands

58 16:50-17:00 Jessica FIEGEMECHANISMS AND CONSEQUENCES OF CELLULAR SURVIVAL FROM INFLUENZA VIRUS INFECTIONUNIVERSITY OF MINNESOTA, Minneapolis, United States

59 17:00-17:10 Taylor WEARYCHARACTERIZATION OF EBOLA VIRUS DEFECTIVE GENOMES IN THE TESTES OF PERSISTENTLY INFECTED NON-HUMAN PRIMATESTEXAS BIOMEDICAL RESEARCH INSTITUTE, San Antonio, United States

60 17:10-17:20 Rik DE SWARTSTUDIES INTO THE MECHANISM OF MEASLES-ASSOCIATED IMMUNE SUPPRESSION DURING AN OUTBREAK OF MEASLES IN THE NETHERLANDSERASMUS MC, Rotterdam, Netherlands

61 17:20-17:30 Cyrille MATHIEUVIRAL ENTRY PROPERTIES REQUIRED FOR FITNESS IN HUMANS REVEALED THROUGH RAPID GENOMIC CHANGE DURING VIRAL ISOLATIONColumbia University Medical Center, New York, United States

62 17:30-17:50 Thomas PIETSCHMANNGENETIC DETERMINANTS OF SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTIONS IN INFANTSTWINCORE- CENTRE FOR EXPERIMENTAL AND CLINICAL INFECTION RESEARCH, Hannover, Germany

63 17:50-18:10 Gustavo PALACIOSTHE EGYPTIAN ROUSETTE GENOME, PROVEN HOST FOR MARBURG VIRUS, REVEALS UNEXPECTED FEATURES OF BAT ANTIVIRAL IMMUNITYUSAMRIID, Frederick, United States

FREEDOM OF VERONA

Thursday June 21

64 09:00-09:20 Amy HARTMANBIPHASIC VASCULAR BREAKDOWN AND INFLUX OF NEUTROPHILS INTO THE BRAIN DURING RIFT VALLEY FEVER VIRUS ENCEPHALITISUNIVERSITY OF PITTSBURGH, Pittsburgh, United States

65 09:20-09:40 Ana FALCONCARDIAC DISORDERS AND SUDDEN DEATH CAUSED UPON HEART INFECTION BY HUMAN PATHOGENIC INFLUENZA A VIRUSCENTER FOR BIOMEDICAL RESEARCH (CIBER), Madrid, Spain

66 09:40-10:00 Aartjan TE VELTHUISABERRANT VIRAL RNAs LINK AVIAN AND PANDEMIC INFLUENZA VIRUS VIRULENCE TO ERRONEOUS RNA POLYMERASE ACTIVITYUNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom

67 10:00-10:10 Jessica SCHULZEINFLUENZA A VIRUS M2 PROTEIN INTERACTS WITH CELLULAR NA,K-ATPASE: DOES IT HAVE A PATHOPHYSIOLOGICAL ROLE IN INFLUENZA PNEUMONIA?ROBERT KOCH INSTITUTE, Berlin, Germany

68 10:10-10:20 Hiroshi UEKIIN VIVO IMAGING CAPTURES THE PATHOPHYSIOLOGICAL CHANGES AND DYNAMICS OF IMMUNE CELLS IN INFLUENZA VIRUS-INFECTED MOUSE LUNGINSTITUTE OF MEDICAL SCIENCE, UNIVERSITY OF TOKYO, Tokyo, Japan

Session Six

FIGHTING AND RESPONDING

11:10-11:20 Sumit CHANDA, Maria Grazia CUSI and Hong JINChairpersons' remarks

69 11:20-11:40 Veronika VON MESSLINGSTOPPING MEASLES IN ITS TRACKS - EFFICACY OF AN ORALLY BIOAVAILABLE ANTIVIRAL AGAINST MEASLES VIRUS IN SQUIRREL MONKEYSPAUL-EHRLICH-INSTITUT, Langen, Germany

70 11:40-12:00 Travis WARRENREMDESIVIR (GS-5734) PROTECTS NONHUMAN PRIMATES AGAINST PATHOGENIC FILOVIRUSESUS ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES, Frederick, United States

71 12:00-12:10 Daniel GOLDHILLTHE MECHANISM OF RESISTANCE TO FAVIPIRAVIR IN INFLUENZAImperial College, London, United Kingdom

72 12:10-12:20 Shuzo URATAIDENTIFICATION OF CALCIUM CHANNEL BLOCKER AS AN ANTI-SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME VIRUS (SFTSV) COMPOUNDNAGASAKI UNIVERSITY, INSTITUTE OF TROPICAL MEDICINE, Nagasaki Japan

73 12:20-12:40 Paul WICHGERS SCHREURBUNYAVIRUS VACCINE DEVELOPMENT BOOSTED BY NOVEL INSIGHTS INTO GENOME REPLICATION AND PACKAGINGWAGENINGEN BIOVETERINARY RESEARCH, Lelystad, Netherlands

74 13:50-14:10 Katie DOORESCONVERGENT IMMUNOLOGICAL SOLUTIONS TO ARGENTINE HEMORRHAGIC FEVER VIRUS NEUTRALIZATIONKING'S COLLEGE LONDON, London, United Kingdom

75 14:10-14:30 Johannes LANGEDIJKSTRUCTURAL BASIS FOR RECOGNITION OF THE CENTRAL CONSERVED REGION OF RSV G BY NEUTRALIZING HUMAN ANTIBODIESJANSSEN VACCINES AND PREVENTION, Leiden, Netherlands

76 14:30-14:50 Kanta SUBBARAOHEADS WIN! HEAD-SPECIFIC B CELLS AND ANTIBODY DOMINATE THE IMMUNE RESPONSE IN A MISMATCHED PRIME-BOOST VACCINE STRATEGY THE PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY, Melbourne, Australia

77 14:50-15:00 Atsuhiro YASUHARATHE POTENTIAL OF HUMAN MONOCLONAL ANTIBODIES THAT RECOGNIZE THE INFLUENZA A(H1N1)PDM09 VIRUS HEMAGGLUTININ RECEPTOR-BINDING SITE AS ANTI-INFLUENZA AGENTS. INSTITUTE OF MEDICAL SCIENCE, UNIVERSITY OF TOKYO, JAPAN

78 15:00-15:10 Miguel Angel MUNOZ ALIACOORDINATE DE-IMMUNIZATION OF MEASLES VIRUS ENVELOPE GLYCOPROTEINS DRIVES THE EMERGENCE OF ANTIGENIC VARIANTSMAYO CLINIC, ROCHESTER, United States

79 16:00-16:20 Ulla BUCHHOLZ LIVE-ATTENUATED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE CANDIDATE WITH NS2 DELETION AND GENETICALLY STABILIZED TEMPERATURE SENSITIVITY MUTATION IS SAFE, IMMUNOGENIC, AND GENETICALLY STABLE IN RSV SERONEGATIVE CHILDRENNIAID, NIH, Bethesda, United States

80 16:20-16:40 David WENTWORTHRESPONSE TO RE-EMERGENCE OF INFLUENZA A(H7N9) VIRUSESCENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States

81 16:40-16:50 Oliver DIBBENH1N1 VACCINE EFFECTIVENESS IN LIVE ATTENUATED INFLUENZA VACCINE IS DRIVEN BY VIRAL REPLICATIVE FITNESS IN THE HUMAN RESPIRATORY TRACT: SELECTION OF A NEW AND IMPROVED VACCINE CANDIDATEMEDIMMUNE, Liverpool, United Kingdom

82 16:50-17:00 Aliza KATZLASSA VIRUS GLYCO-PROTEIN1 CONFORMATIONAL CHANGES – A POSSIBLE ROLE FOR IMMUNE EVASIONWEIZMANN INSTITUTE, Jerusalem, Israel

83 17:00-17:20 Diane GRIFFINMEASLES WILD TYPE AND VACCINE VIRUSES: REPLICATION AND IMMUNE RESPONSES IN RHESUS MACAQUESJOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH, United States

REMOVE SESSION TWO POSTERSUNREMOVED POSTERS AFTER 17.45 WILL BE DISCARDED!

GALA DINNER

BUSES DEPART GRAN GUARDIA 18:45

RETURN FROM 22:30-00:00

Gala Dinner

VILLA ARVEDI

Buses leave from the front of Gran Guardia at 18:45Tonight we dine, dance and drink wines from the Vento region as we take a tripinto the countryside to a beautiful 17th century mansion. Sip aperitifs on theporch, chat in the orangery and study the frescoed ceilings of this wonderfulItalian villa. In the time honored tradition of NSV Meetings, the Gala Dinner isalways something to remember!

Buses return to Verona from 22:30-00:00

Session Seven

Friday June 22

EMERGING AND EVOLVING

09:30-09:40 Alain KOHL and Connie SCHMALJOHNChairpersons' remarks

84 09:40-10:00 Jens KUHNMEGATAXONOMY OF NEGATIVE-SENSE RNA VIRUSES: PHYLUM “NEGARNAVIRICOTA” NIH/NIAID/DCR/INTEGRATED RESEARCH FACILITY AT FORT DETRICK, Frederick, United States

85 10:00-10:10 Hector MORENO BORREGO ISOLATION, CHARACTERIZATION, AND RAPID ADAPTATION OF TICK-BORNE ARENAVIRUSCentre Hospitalier Universitaire Vaudoise (CHUV), Lausanne (Switzerland)Switzerland

86 10:10-10:20 Rebecca JOHNSONCHARACTERISATION OF A NOVEL PARAMYXOVIRUS ISOLATED FROM PTEROPID BAT URINECSIRO-AUSTRALIAN ANIMAL HEALTH LABORATORY, East Geelong, Australia

87 10:20-10:30 Mukai YAHIROINVESTIGATION OF THE BIOLOGICAL ROLE OF AN ENDOGENOUS BORNAVIRUS-LIKE ELEMENT IN MINIOPTERID BAT GENOMESINSTITUTE FOR FRONTIER LIFE AND MEDICAL SCIENCES , KYOTO UNIVERSITY, Kyoto, Japan

88 10:30-10:50 Branka HORVATNIPAH VIRUS W PROTEIN MODULATES THE NF-ΚB SIGNALING PATHWAY BY TARGETING A HOST SCAFFOLD PROTEINCIRI, Lyon, France

COFFEE 10:50-11:30

Friday June 22EMERGING AND EVOLVING

89 11:30-11:50 John STEEL AVIAN INFLUENZA VIRUS M SEGMENT GENE EXPRESSION IS DYSREGULATED IN MAMMALIAN CELLS, LEADING TO A BLOCK IN AUTOPHAGY AND RESTRICTED VIRAL GROWTHEMORY UNIVERSITY, Atlanta, United States

90 11:50-12:00 Kevin CIMINSKI ASSESSMENT OF THE ZOONOTIC POTENTIAL OF THE BAT INFLUENZA A VIRUS H18N11UNIVERSITY MEDICAL CENTER FREIBURG CENTER FOR MICROBIOLOGY AND HYGIENE INSTITUTE OF VIROLOGY, Freiburg, Germany

91 12:00-12:10 Cyril LENOUENSELECTIVE PRESSURE ON RESPIRATORY SYNCYTIAL VIRUS BEARING CODON-PAIR DEOPTIMIZED F AND G ORFS GENERATES INTERNAL-DELETION GENOMES THAT PARADOXICALLY RESCUE VIRAL REPLICATIONNIH/NIAID/LID, BETHESDA, United States

92 12:10-12:20 Maino TAHARAA NEW OPTICALLY CONTROLLABLE MEASLES VIRUS VECTORNATIONAL INSTITUTE OF INFECTIOUS DISEASES, Musashimurayama, Japan

93 12:20-12:40 Benjamin TENOEVERLOSS OF RNAi WAS REQUIRED FOR THE INVENTION OF NEGATIVE-STRANDED RNA VIRUSESICAHN SCHOOL OF MEDICINE, New York, United States

12:40-12:45 CLOSING REMARKS

LUNCH WITH WINE

Poster Session One

Poster Prizes:

We are grateful to the Microbiology Society and the Journal ofGeneral Virology, Nature Microbiology, Nature Reviews inMicrobiology and The European Society for Virology forsponsoring seven posters prizes. If you are an early careerresearcher who would like your research considered for anaward just put the heart shaped sticker you’ll find in theconference bag beside your poster to let the judges know.

BREAKING AND ENTERINGP001 Jeremy Luban

INSIGHT INTO THE FUSION MECHANISM GLEANED FROM AN EBOLA VIRUS GLYCOPROTEIN MUTANT THAT DOMINATED THE 2013-2016 PANDEMICUNIVERSITY OF MASSACHUSETTS MED SCHOOL, Worcester, United States

P002 Masato TsurudomeTHE HEMAGGLUTININ-NEURAMINIDASE (HN) HEAD DOMAIN AND THE FUSION (F) PROTEIN STALK DOMAIN OF THE PARAINFLUENZA VIRUSES AFFECT THE SPECIFICITY OF THE HN-F INTERACTIONCHUBU UNIVERSITY, Kasugai, Japan

P003 Dalan BaileySTRUCTURE-GUIDED IDENTIFICATION OF MORBILLIVIRUSES WITH ZOONOTIC POTENTIALThe Pirbright Institute Guildford, United Kingdom

P004 Lauren Byrd-LeotisNATURAL GLYCAN RECEPTORS FOR INFLUENZA VIRUS IN HUMAN LUNGHARVARD MEDICAL SCHOOL, Boston, United States

P005 Gert ZimmerTHE CRITICAL ROLE OF HEMAGGLUTININ (HA) IN TRANSMISSION OF DUCK-ORIGIN H5NX LOW-PATHOGENIC AVIAN INFLUENZA VIRUSES IN CHICKENSINSTITUTE OF VIROLOGY AND IMMUNOLOGY (IVI), Mittelhäusern, Switzerland

P006 Megan SloughTWO POINT MUTATIONS IN THE HANTAAN VIRUS GLYCOPROTEIN COMPLEX AFFORD THE GENERATION OF A HIGHLY INFECTIOUS REPLICATION-COMPETENT RECOMBINANT VSVALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States

P007 Giulia TorrianiHANTAVIRUS ENTRY INTO HUMAN RESPIRATORY EPITHELIAL CELLS INVOLVES MACROPINOCYTOSISUNIVERSITY HOSPITAL CENTER AND UNIVERSITY OF LAUSANNE, Lausanne, Switzerland

P008 Jennifer MayorHANTAVIRUSES ENTER INTO HUMAN AIRWAY EPITHELIUM USING PHOSPHATIDYLSERINE RECEPTORS TIM-1 AND AXLLAUSANNE UNIVERSITY HOSPITAL, Lausanne, Switzerland

P009 Rhys PryceSTRUCTURAL BASIS FOR DIFFERENTIAL EPHRIN-MEDIATED HOST-CELL ENTRY PATHWAYS OF HENIPAVIRUSESDIVISION OF STRUCTURAL BIOLOGY, UNIVERSITY OF OXFORD, Oxford, United Kingdom

P010 Tatsunari KondohSINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN NIEMANN-PICK C1 INFLUENCE ENTRY OF FILOVIRUSES INTO CELLSDIVISION OF GLOBAL EPIDEMIOLOGY, RESEARCH CENTER FOR ZOONOSIS CONTROL, HOKKAIDO UNIVERSITY, Sapporo, Japan

P011 Michael HerrenDUAL-REGULATORY ROLE OF THE MORBILLIVIRUS ATTACHMENT PROTEIN HEAD-TO-STALK LINKER MODULE IN MEMBRANE FUSION TRIGGERINGUniversity of Bern, Bern, Switzerland

P012 Manasi Ajit TamhankarEBOLA VIRUS ENTRY AND EGRESS IN POLARIZED EPITHELIAL CELLSTEXAS BIOMEDICAL RESEARCH INSTITUTE, San Antonio, United States

P013 Yves GaudinBIOCHEMICAL AND STRUCTURAL CHARACTERIZATION OF VSV (NEW JERSEY STRAIN) GLYCOPROTEININSTITUT DE BIOLOGIE INTÉGRATIVE DE LA CELLULE, CNRS, Gif sur Yvette, France

P014 Annelies StevaertINFLUENZA VIRUS ENTRY VIA INTERPLAY BETWEEN PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA AND GM3 GANGLIOSIDE: A VALID ROUTE FOR HOST-TARGETED ANTIVIRAL INTERVENTIONRega Institute for Medical Research, KU Leuven – University of Leuven, Leuve, Belgium

P015 Nadine KrügerVIRAL ENTRY AND REPLICATION OF BAT-DERIVED MUMPS VIRUSUniversity of Veterinary Medicine Hannover, Hannover, Germany

P016 Mark J.G. BakkersA GENOME-WIDE GENETIC SCREEN UNCOVERS A ROLE FOR HEPARAN SULFATE IN LCMV ENTRYHARVARD MEDICAL SCHOOL, Boston, United States

P017 Lara M KleinfelterCHARACTERIZATION OF HANTAVIRUS ENTRY THROUGH LIVE-CELL IMAGINGALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States

P018 Weng Ming NgSTRUCTURAL CLASSES OF OLD WORLD ARENAVIRUS GP1 ATTACHMENT GLYCOPROTEINDivision of Structural Biology, University of Oxford, Oxford, United Kingdom

P019 Robert StassARCHITECTURE OF THE METASTABLE HANTAVIRUS ENVELOPESTRUBI, UNIVERSITY OF OXFORD, Oxford, United Kingdom

P020 Svenja Mareike WiechertCHARACTERIZATION OF DETERMINANTS FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS SPECIES SPECIFIC CELL ENTRYTWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany

P021 Kristopher AzarmTHE NOVEL CEDAR HENIPAVIRUS ATTACHMENT GLYCOPROTEIN DISPLAYS IDIOSYNCRATIC USAGE OF THE HUMAN EPHRIN CELL SURFACE RECEPTORSICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States

P022 Emma PunchPOTASSIUM ACTIVATES THE FUSION MACHINERY OF HAZARA VIRUS THROUGH SPIKE CONFORMATIONAL CHANGEUniversity of Leeds, United Kingdom

EXPRESSING AND MULTIPLYINGP023 Edward Hutchinson

COMPETING LYSINE MODIFICATIONS IN INFLUENZA VIRUS PROTEINS.MRC-UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH, Glasgow, United Kingdom

P024 Ming LuoROLE OF THE NUCLEOCAPSID IN REGULATION OF VIRAL RNA SYNTHESISGEORGIA STATE UNIVERSITY, Atlanta, United States

P025 Withdrawn P026 Thibaut Crepin

NUCLEAR IMPORT AND ASSEMBLY OF INFLUENZA VIRUS REPLICATION MACHINERYIBS, Univ. Grenoble Alpes, CEA, CNRS, Grenoble, France

P027 Jean-Francois EleouetDEPHOSPHORYLATION OF RESPIRATORY SYNCYTIAL M2-1 PROTEIN BY THE CELLULAR PHOSPHATASE PP1 IS REQUIRED FOR ITS mRNA BINDING ABILITYINRA, Jouy en Josas, France

P028 Jean-Francois EleouetTHE ISOLATION AND CHARACTERIZATION OF A N°-P COMPLEX OF THE RESPIRATORY SYNCYTIAL VIRUS OPENS THE WAY TO THE RATIONAL DESIGN OF NEW ANTIVIRALSINRA, Jouy en Josas, France

P029 Bo LiangMECHANISM OF RESPIRATORY SYNCYTIAL VIRUS RNA SYNTHESISEMORY UNIVERSITY SCHOOL OF MEDICINE, Atlanta, United States

P030 Gaya AmarasingheSTRUCTURAL BASIS FOR REGULATION OF FILOVIRAL NUCLEOPROTEIN (NP) BY VP35 DURING VIRAL RNA SYNTHESISWASHINGTON UNIVERSITY SCHOOL OF MEDICINE, St. Louis, United States

P031 Kah-Whye PengFIRST IN HUMAN STUDIES OF ONCOLYTIC VESICULAR STOMATITIS VIRUSES ENCODING INTERFERON FOR CANCER THERAPYMAYO CLINIC, Rochester, United States

P032 Elizabeth SloanSTART-SNATCHING: A POTENTIAL NOVEL MECHANISM FOR TRANSLATION INITIATION IN SEGMENTED NEGATIVE-SENSE RNA VIRUSESCVR-UNIVERSITY OF GLASGOW, Glasgow, United Kingdom

P033 Maria RosenthalSTRUCTURAL INSIGHTS INTO REPTARENAVIRUS CAP-SNATCHING MACHINERYBERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, Hamburg, Germany

P034 Itziar Serna MartinA MECHANISM FOR THE ACTIVATION OF THE INFLUENZA VIRUS TRANSCRIPTASEUNIVERSITY OF OXFORD, Oxford, United Kingdom

P035 Kohei OishiN-TERMINAL ACETYLATION BY NATB IS REQUIRED FOR THE SHUTOFF ACTIVITY OF INFLUENZA A VIRUS PA-XUNIVERSITY OF TOKYO, Minato-ku, Japan

P036 Yuki TakamatsuIDENTIFICATION OF AN EBOLA VIRUS VP30-SPECIFIC KINASE THAT REGULATES VIRAL TRANSCRIPTIONINSTITUTE OF VIROLOGY, PHILIPPS UNIVERSITY MARBURG, Marburg, Germany

P037 Janne TynellFUNCTIONAL CHARACTERIZATION OF THE HANTAVIRUS S SEGMENT UNTRANSLATED REGIONKAROLINSKA INSTITUTET, Stockholm, Sweden

P038 Denis GerlierDETAILED MAPPING OF THE VARIOUS POLYMERASE COFACTOR FUNCTIONS WITHIN THE PHOSPHOPROTEIN OF MEASLES VIRUSCIRI INSERM U1111, CNRS UMR5307, UNIVERSITY LYON 1, ENS LYON, UNIV LYON, Lyon, France

P039 Marie-Anne Rameix-WeltiVIRAL TRANSCRIPTION DRIVES THE FORMATION OF VIRAL RNA GRANULES WITHIN RESPIRATORY SYNCYTIAL VIRUS INCLUSION BODIESVERSAILLES SAINT QUENTIN UNIVERSITY, MONTIGNY-LE-BRETONNEUX, France

P040 Bernard DelmasINFLUENZA VIRUS RNA-POLYMERASE: TEMPERATURE-SENSITIVE MUTANTS IN PB1 DISPLAY A DEFECT IN NUCLEAR TARGETING OF THE PA-PB1 DIMERINRA, Jouy-en-Josas, France

P041 Monique SpronkenOPTIMISING INFLUENZA A REPORTER VIRUSES BY IN VIVO PASSAGINGERASMUS MEDICAL CENTRE, Rotterdam, Netherlands

P042 Timothy James MottramRIFT VALLEY FEVER PHLEBOVIRUS NUCLEOPROTEIN PROTEOMIC STUDIES IDENTIFY IMPORTANT WNT PATHWAY INTERACTIONSMRC-UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH, Glasgow, United Kingdom

P043 Jacquline Carson RisalvatoIDENTIFICATION OF MUMPS VIRUS NUCLEOPROTEIN RESIDUE ENHANCES PRODUCTION OF DEFECTIVE INTERFERING PARTICLESUNIVERSITY OF GEORGIA, Athens, United States

P044 Shohei KojimaALTERNATIVE SPLICING UNMASKS AN ENDOPLASMIC RETICULUM TARGETING SIGNAL OF BORNA DISEASE VIRUS NUCLEOPROTEINKYOTO UNIVERSITY, Kyoto, Japan

P045 Alexander KoehlerTHE OLIGOMERIC STATE OF MARBURG VIRUS VP40 INFLUENCES ITS ROLE IN MODULATING VIRAL TRANSCRIPTION AND REPLICATIONPHILIPPS UNIVERSITY MARBURG, Marburg, Germany

P046 Andre BertranTOWARDS THE DEVELOPMENT OF REVERSE GENETICS SYSTEMS FOR TOMATO SPOTTED WILT VIRUSWAGENINGEN UNIVERSITY, Wageningen, Netherlands

P047 Nadine BiedenkopfROLE OF HOST PHOSPHATASE PP2A IN FILOVIRUS REPLICATION CYCLEPHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany

P048 Max RennerSTRUCTURAL CHARACTERISATION OF THE METAPNEUMOVIRUS TRANSCRIPTASE COMPONENTS P AND M2-1 BY MODELLING, CRYSTALLOGRAPHY, AND SAXSUNIVERSITY OF OXFORD, Oxford, United Kingdom

P049 Natasha Louise Tilston-LunelCHARACTERIZING DEFECTIVE VIRAL GENOMES OF CANINE DISTEMPER VIRUSBOSTON UNIVERISTY, Boston, United States

P050 Joshua HorwitzRABIES VIRUS L-PROTEIN C-TERMINAL DOMAINS ARE STRUCTURALLY COORDINATED BY THE N-TERMINUS OF THE VIRAL PHOSPHOPROTEINHARVARD MEDICAL SCHOOL, Boston, United States

P051 Charles-Adrien RichardEFFECT OF MUTATIONS IN THE GENE-END SEQUENCE ON RSV TRANSCRIPTIONINRA, Jouy en Josas, France

P052 Koyu HaraTHE C-TERMINAL FRAGMENT OF THE RESPIRATORY SYNCYTIAL VIRUS PHOSPHOPROTEIN INHIBITS THE VIRAL POLYMERASE ACTIVITYKURUME UNIVERSITY SCHOOL OF MEDICINE, Kurume, Japan

P053 Akihiro SugaiINVESTIGATION OF A PROTEIN KINASE RESPONSIBLE FOR THE PHOSPHORYLATION OF MEASLES VIRUS NUCLEOPROTEINTHE UNIVERSITY OF TOKYO, Tokyo, Japan

P054 Ashley Lauren SilviaDISCOVERY AND DETECTION OF EBOV-ENCODED MICRORNA-LIKE MOLECULES IN INFECTED CELLS AND NON-HUMAN PRIMATESTEXAS BIOMEDICAL RESEARCH INSTITUTE, San Antonio, United States

P055 Christophe CardoneSTRUCTURAL CHARACTERIZATION OF RSV PHOSPHOPROTEINCNRS ICSN, Gif-sur-Yvette Cedex, France

P056 Alex WalkerDETECTION AND CHARACTERISATION OF INFLUENZA VIRUS RNA POLYMERASE DIMERS USING BIMOLECULAR FLUORESCENCE COMPLEMENTATION (BIFC)University of Oxford, United Kingdom

P057 Joseph GouldTHE CONNECTOR DOMAIN OF VESICULAR STOMATITIS VIRUS LARGE PROTEIN IS AN ACCEPTOR SITE FOR PHOSPHOPROTEIN BINDINGUNIVERSITY OF ALABAMA AT BIRMINGHAM, Birmingham, United States

P058 Antoine SCHRAMMMEASLES VIRUS PHOSPHOPROTEIN MULTIMERIZATION DOMAIN: COILED-COIL FEATURES AND FUNCTIONAFMB CNRS, Marseille, France

P059 Boris BogdanowCOMBINED PROTEOMICS AND TRANSCRIPTOMICS SUGGESTS THAT M1 mRNA SPLICING INFLUENCES IAV HOST SPECIFICITYMDC BERLIN, Berlin, Germany

P060 Atsushi KawaguchiMXA-DEPENDENT INFLAMMASOME RESTRICTS INFLUENZA A VIRUS INFECTION IN RESPIRATORY EPITHELIAL CELLSUNIVERSITY OF TSUKUBA, Tsukuba, Japan

P061 Ronald DijkmanCHARACTERIZATION OF VIRUS - HOST INTERACTION DYNAMICS WITHIN THE RESPIRATORY EPITHELIUMINSTITUTE OF VIROLOGY AND IMMUNOLOGY IVI, Bern, Switzerland

P062 Yan ZhouNUCLEAR RESIDENT RIG-I SENSES INFLUENZA A VIRUS REPLICATION MOUNTING AN ANTIVIRAL RESPONSEUNIVERSITY OF SASKATCHEWAN, Saskatoon, Canada

P063 Toru TakimotoSPECIFICITY AND FUNCTIONAL INTERPLAY BETWEEN INFLUENZA VIRUS PA-X AND NS1 SHUTOFF ACTIVITYUNIVERSITY OF ROCHESTER MEDICAL CENTER, Rochester, United States

P064 Georg HerrlerTHE AIRWAY EPITHELIUM MAINTAINS THE BARRIER FUNCTION AFTER INFLUENZA VIRUS INFECTION DESPITE THE EXTENSIVE LOSS OF CILIATED CELLSSTIFTUNG TIERÄRZTLICHE HOCHSCHULE HANNOVER, Hannover, Germany

P065 Stefan PöhlmannINSIGHTS INTO TETHERIN COUNTERACTION BY THE EBOLA VIRUS GLYCOPROTEINGERMAN PRIMATE CENTER, Göttingen, Germany

P066 David L V BauerINFLUENZA VIRUS MOUNTS A TWO-PRONGED ATTACK ON RNA POLYMERASE II TRANSCRIPTIONUNIVERSITY OF OXFORD, Oxford, United Kingdom

P067 Christian Karl PfallerFLYING UNDER THE (R)ADAR: ADAR1-P150 EDITING COUNTERACTS INTRINSIC IMMUNITY ACTIVATION BY SELF AND VIRAL DOUBLE STRANDED RNAMAYO CLINIC, Rochester, United States

P068 Laura Martin-SanchoGLOBAL SIRNA SCREEN IN HUMAN MACROPHAGES IDENTIFY TBC1D5 AS A NOVEL CELLULAR RESTRICTION FACTOR FOR INFLUENZA A VIRUS REPLICATIONSBP Medical Discovery Institute, San Diego, United States

P069 Shashank TripathiINTERFERENCE BEFORE INTERFERON: CHARACTERIZATION OF INTERFERON SIGNALING INDEPENDENT ANTIVIRAL INNATE IMMUNITY AGAINST INFLUENZA A VIRUSESICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States

P070 Jonathan Colin GuitoCOMPARATIVE TRANSCRIPTOMICS REVEAL THAT ANTIVIRAL GENE EXPRESSION IN THE EGYPTIAN ROUSETTE BAT IS ANTAGONIZED IN VITRO BY MARBURG VIRUS INFECTIONCENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States

P071 Anna BruchezTRANSPOSON-MEDIATED ACTIVATION SCREENING IN HUMAN CELLS IDENTIFIES THE CLASS II TRANSACTIVATOR AS A RESTRICTION FACTOR FOR EBOLABENAROYA RESEARCH INSTITUTE, Seattle, United States

P072 Jelena AndrejevaPARAINFLUENZA VIRUS 5 (PIV5) P PROTEIN IS MODIFIED IN RESPONSE TO IFNΑ, AND THIS INHIBITS PIV5 INFECTIONUNIVERSITY OF ST. ANDREWS, SCOTLAND, UK St. Andrews, United Kingdom

P073 Megan R. EdwardsSTRUCTURAL BASIS OF IMPORTIN ALPHA SPECIFICITY FOR HENIPAVIRUS W PROTEINSGEORGIA STATE UNIVERSITY, Atlanta , United States

P074 Agnieszka SzemielPUUMALA HANTAVIRUS INFECTION MODULATES THE CIRCADIAN CLOCKMRC - University of Glasgow Centre for Virus Research, Glasgow, United Kingdom

P075 Kristina L. SchierhornHUR RESTRICTS EBOLA VIRUS REPLICATIONKING'S COLLEGE LONDON, London, United Kingdom

P076 Sara ClohiseyTERMINAL DEPTH SINGLE-MOLECULE SEQUENCING OF CAPPED TRANSCRIPTS REVEALS HOST-PATHOGEN DYNAMICS IN HUMAN MACROPHAGES.THE ROSLIN INSTITUTE, Edinburgh, United Kingdom

P077 Rokusuke YoshikawaIS THE PATHOGENICITY OF SFTSV DETERMINED BY VIRAL NSS PROTEIN?NAGASAKI UNIVERSITY, Nagasaki-shi, Japan

P078 Julianna HanREGULATION OF CELL INTRINSIC IMMUNITY BY THE TRANSCRIPTIONAL REPRESSOR CAPICUATHE UNIVERSITY OF CHICAGO, Chicago, United States

P079 Kai RogersACUTE PLASMODIUM INFECTION PROMOTES RESISTANCE TO EBOLA VIRUS VIA TYPE 1 IMMUNITY IN MACROPHAGESUNIVERSITY OF IOWA, Iowa City, United States

P080 Miyu MoriyamaRECOGNITION OF INFLUENZA A VIRUS BY DNA SENSORSUNIVERSITY OF TOKYO, Tokyo, Japan

P081 Diego CantoniREGULATION OF CELL DEATH BY THE EBOLAVIRUS VP24 PROTEINUNIVERSITY OF KENT, Canterbury, United Kingdom

P082 WithdrawnP083 Jennifer Wuerth

SANDFLY FEVER SICILIAN VIRUS NSS SPECIFICALLY TARGETS IRF3 TO INHIBIT TYPE I INTERFERON INDUCTIONJUSTUS-LIEBIG UNIVERSITY GIESSEN, Giessen, Germany

P084 Rute Maria PintoIDENTIFICATION OF TWO NEW POLYPEPTIDES FROM SEGMENT 2 OF IAV THAT MODULATE THE TYPE I INTERFERON RESPONSETHE ROSLIN INSTITUTE, THE UNIVERSITY OF EDINBURGH, Edinburgh, United Kingdom

P085 Colleen JonssonEARLY HOST RESPONSES OF HUMAN PRIMARY LUNG MICROVASCULAR ENDOTHELIAL CELLS AND RESTING MONOCYTES TO BLACK CREEK CANAL ORTHOHANTAVIRUS (BCCV)UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER, Memphis, United States

P086 Takeshi IchinoheTWO CONSERVED AMINO ACIDS WITHIN THE NSS PROTEIN OF SFTS VIRUS ARE ESSENTIAL FOR ANTI-INTERFERON ACTIVITYUNIVERSITY OF TOKYO, Tokyo, Japan

P087 Withdrawn

P088 Saori SakabeANATOMY OF CYTOTOXIC T LYMPHOCYTE RESPONSE DURING THE 2013-2016 EBOLA OUTBREAK IN WEST AFRICATHE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States

P089 Stéphanie DevignotTHE OVARIAN TUMOR (OTU) DOMAIN OF CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS (CCHFV) INFLUENCES THE POLYMERASE RDRP ACTIVITY, BUT DOES NOT COUNTERACT INNATE IMMUNITYINSTITUTE FOR VIROLOGY, FB10 VETERINARY MEDICINE, Giessen, Germany

P090 Asuka YoshidaNIPAH VIRUS C PROTEIN INHIBITS INFLAMMATORY CYTOKINE INDUCTION BY INTERACTION WITH PHOSPHATASE 2A INHIBITOR.THE INSTITUTE OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO, Tokyo, Japan

P091 Olivier MoncorgéMX1 REQUIREMENTS FOR INFLUENZA A VIRUS RESTRICTIONIRIM, MONTPELLIER, France

P092 Claudia GandolfoUBIQUITINATION OF TOSCANA VIRUS NSS UNDERMINES ITS STABILITY AND HAS A ROLE IN RIG-I DEGRADATIONUniversity of Siena, Siena, Italy

P093 Markus HoffmannTHE GLYCOPROTEIN OF VESICULAR STOMATITIS VIRUS IS A TETHERIN ANTAGONIST IN TRANSFECTED BUT NOT INFECTED CELLSDEUTSCHES PRIMATENZENTRUM GMBH, LEIBNIZ-INSTITUT FÜR PRIMATENFORSCHUNG, Göttingen, Germany

P094 Keisuke OhtaHUMAN PARAINFLUENZA VIRUS TYPE 2 V PROTEIN INDUCES FILAMENTOUS ACTIN FORMATIONWAKAYAMA MEDICAL UNIVERSITY, Wakayama, Japan

P095 Yusuke MatsumotoREGULATION OF HAZARA VIRUS GROWTH THROUGH APOPTOSIS INHIBITION BY VIRAL NUCLEOPROTEINSCHOOL OF MEDICINE, WAKAYAMA MEDICAL UNIVERSITY, Wakayama, Japan

P096 Hiroki SatoMEASLES VIRUS INFECTION TRIGGERS cGAS-DEPENDENT ANTIVIRAL RESPONSES.INSTITUTE OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO, Tokyo, Japan

P097 Valentina VolchkovaEBOLA VIRUS INHIBITS CELLULAR NRF2-DEPENDENT ANTIOXIDANT SIGNALING PATHWAY VIA EXPRESSION OF STRUCTURAL PROTEIN VP24.CIRI 1111, Lyon, France

P098 Tomoyuki HondaSMALL RNAS DERIVED FROM AN ENDOGENOUS BORNAVIRUS ELEMENT IN MICE SUPPRESS EXPRESSION OF A REPORTER WITH BORNA DISEASE VIRUS SEQUENCES IN GC2 CELLSOSAKA UNIVERISTY, Osaka, Japan

P099 WithdrawnP100 Jorge Vera Otarola

THE NSS PROTEIN FROM THE ANDES VIRUS INHIBITS THE TYPE I IFN RESPONSE PATHWAYLABORATORIO DE VIROLOGÍA MOLECULAR, INSTITUTO MILENIO DE INMUNOLOGÍA E INMUNOTERAPIA, CENTRO DE INVESTIGACIONES MÉDICAS, DEPARTAMENTO DE ENFERMEDADES INFECCIOSAS E INMUNOLOGÍA PEDIÁTRICA , ESCUELA DE MEDICINA, PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE, Santiago, Chile

P101 Sangjoon LeeINFLUENZA A VIRUS INFECTION TRIGGERS PYROPTOSIS AND APOPTOSIS OF RESPIRATORY EPITHELIAL CELLS THROUGH TYPE I IFN SIGNALING PATHWAY IN A MUTUALLY EXCLUSIVE MANNERUNIVERSITY OF TSUKUBA, Tsukuba, Japan

P102 Whitney ManhartDEVELOPMENT OF AN EBOLA VIRUS INFECTION MODEL USING IPSC-DERIVED HEPATOCYTESBOSTON UNIVERSITY SCHOOL OF MEDICINE, Boston, United States

P103 Simone LauKNOCKING ON THE NUCLEAR DOOR: RIFT VALLEY FEVER VIRUS VIRULENCE FACTOR NSS TARGETS NUCLEAR-CYTOPLASMIC TRANSPORTJustus-Liebig University, Giessen, Germany

P104 Eline SoetensSINGLE DOMAIN ANTIBODIES TO PROBE THE ANTIVIRAL FUNCTION OF INTERFERON-INDUCED MX1 PROTEINSVIB/UGENT, Anzegem, Belgium

P105 Mako YanaiINVOLVEMENT OF ADAR2 IN BORNA DISEASE VIRUS INFECTIONKYOTO UNIVERSITY, Kyoto, Japan

BUILDING AND ESCAPINGP106 WithdrawnP107 Tao Deng

CHARACTERIZATION OF THE H1 SUBTYPE-SPECIFIC NONCODING REGIONS OF INFLUENZA A VIRUSES IN REGULATING HA SEGMENT VIRION INCORPORATIONINSTITUTE OF PATHOGEN BIOLOGY,CHINESE ACADEMY OF MEDICAL SCIENCES, Beijing, China

P108 Rafael A. MedinaTHE COMPLEXITY OF THE N-GLYCOSYLATIONS NEAR SITE SA ON THE HA OF THE INFLUENZA A MODULATE ITS ANTIGENIC PROPERTY AND THE AVIDITY FOR ITS RECEPTORPONTIFICIA UNIVERSIDAD CATOLICA DE CHILE, Santiago, Chile

P109 WithdrawnP110 Marc Ringel

ASSEMBLY AND SPREAD OF NIPAH VIRUS ENCODING A MATRIX PROTEIN WITH A DEFECTIVE NUCLEAR EXPORT SIGNALPHILIPPS-UNIVERSITY MARBURG, INSTITUTE OF VIROLOGY, Marburg, Germany

P111 Yvonne BörgelingTYROSINE 132 OF INFLUENZA A VIRUS MATRIX PROTEIN 1 IS ESSENTIAL FOR EFFICIENT VIRAL GENOME PACKAGING AND PARTICLE ASSEMBLYUNIVERSITY OF MUENSTER, Münster, Germany

P112 Christopher ZieglerARENAVIRUS EXIT, UBIQUITIN, AND THE ESCRT PATHWAYUNIVERSITY OF VERMONT, Burlington, United States

P113 Olga DolnikTHE IQGAP FAMILY PROTEINS IN MARBURG VIRUS INFECTIONPHILIPPS-UNIVERSITY MARBURG, Marburg, Germany

P114 Sho MiyamotoTHE VRNA-VRNA INTERACTIONS IMPORTANT FOR HA VRNA PACKAGING OF THE INFLUENZA A VIRUSINSTITUTE FOR FRONTIER LIFE AND MEDICAL SCIENCES, KYOTO UNIVERSITY, Kyoto, Japan

P115 Bernadeta DadonaiteANALYSIS OF HIGHER ORDER RNA STRUCTURES IN THE INFLUENZA A VIRUS GENOMEUNIVERSITY OF OXFORD, Oxford, United Kingdom

P116 Matthew BadhamTHE INFLUENZA VIRUS M2 PROTEIN CYTOPLASMIC TAIL INTERACTS WITH HOST PROTEINS TO FACILITATE VIRAL MORPHOGENESIS.UNIVERSITY OF KENT, Canterbury, United Kingdom

P117 Carina ConceicaoEVIDENCE FOR A LINK BETWEEN BUDDING MORPHOLOGY AND TRANSMISSION OF AVIAN INFLUENZA A VIRUSESTHE ROSLIN INSTITUTE, UNIVERSITY OF EDINBURGH, Roslin, United Kingdom

P118 Sarah FehlingCHARACTERIZATION OF THE MOLECULAR MECHANISMS UNDERLYING INTERACTION OF LASSA VIRUS Z PROTEIN WITH THE HOST FACTOR KIF13APHILIPPS UNIVERSITY MARBURG, Marburg, Germany

P119 Fumitaka MomoseACCESSIBILITY ASSESSMENT OF THE TERMINAL REGION OF INFLUENZA A VIRUS GENOME SEGMENT BY FLUORESCENCE IN SITU HYBRIDIZATIONKITASATO UNIVERSITY, Minato-ku, Japan

P120 Takashi IrieDETAILED FUNCTIONAL MAPPING OF THE PARAMYXOVIRUS ACCESSORY PROTEINS IN VIRAL INFECTIONHIROSHIMA UNIVERSITY, Hiroshima, Japan

P121 Maria GüntherINFLUENCE OF NUCLEAR LOCALIZATION SITES IN HENDRA VIRUS MATRIX PROTEIN ON INTERACTION WITH ANP32B AND VIRUS LIKE PARTICLE FORMATIONFriedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany

P122 Nicole KadziochSURFACE-EXPOSED LYSINE RESIDUES OF THE CDV MATRIX PROTEIN CONTRIBUTE TO MEMBRANE ASSOCIATION AND BUDDING ACTIVITYUniversity of Bern, Vetsuisse Faculty, Bern, Switzerland

P123 Matthieu GastINVESTIGATION OF Α-HELICES OF CANINE DISTEMPER VIRUS MATRIX PROTEIN IN OLIGOMERIZATION AND MEMBRANE BUDDING ACTIVITYUniversity of Bern Vetuisse Faculty, Bern, Switzerland

Poster Session Two

Poster prizes provided by:

DAMAGING AND SPREADINGP124 Chieko Kai

A RECOMBINANT MEASLES VIRUS BLIND TO SLAM IS A PROMISING CANDIDATE FOR SCIRRHOUS GASTRIC CANCER THERAPYTHE UNIVERSITY OF TOKYO, Tokyo, Japan

P125 Amy HartmanRIFT VALLEY FEVER VIRUS INFECTION OF PREGNANT SPRAGUE-DAWLEY RATS RESULTS IN FETAL INFECTION AND DEMISEUNIVERSITY OF PITTSBURGH, Pittsburgh, United States

P126 Douglas J. LaCountGENOME-WIDE ANALYSES OF FILOVIRUS-HOST CELL PROTEIN-PROTEIN INTERACTIONSPURDUE UNIVERSITY, West Lafayette, United States

P127 Georg HerrlerINFLUENZA VIRUSES AND PARAMYXOVIRUSES ENHANCE THE ADHERENCE AND INVASION PROPERTIES OF STREPTOCOCCI BY A SIALIC ACID-DEPENDENT INTERACTION WITH THE CAPSULAR POLYSACCHARIDESTIFTUNG TIERÄRZTLICHE HOCHSCHULE HANNOVER, Hannover, Germany

P128 Angela RasmussenSEX-DEPENDENT HOST RESPONSES ASSOCIATED WITH EBOLA VIRUS PATHOGENICITYCOLUMBIA UNIVERSITY, New York, United States

P129 WithdrawnP130 Alexander Ghanem

WHOLE GENOME CRISPR/CAS9-KO SCREEN REVEALS PROTEIN KINASE R (PKR) AS THE KEY PLAYER IN RABIES VIRUS CYTOTOXICITYLMU MUNICH, Munich, Germany

P131 Brian HuaFUNCTIONAL ANALYSIS OF A CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS GENOME FROM TICKS IDENTIFIES A GLYCOPROTEIN VARIANT THAT POORLY INFECTS HUMAN CELLSCENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States

P132 Stephen R WelchTISSUE TROPISM AND DISSEMINATION OF CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS IN IFNAR KNOCKOUT MICE VISUALIZED BY IN SITU FLUORESCENT IMAGINGCENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States

P133 Lisa OestereichHUMAN IMMUNE RESPONSES TO LASSA VIRUS INFECTION IN NIGERIABERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, Hamburg, Germany

P134 Shadia OmarIDENTIFICATION OF ESCAPE MUTANTS OF EQUINE INFLUENZA USING POLYCLONAL SERA AND MONOCLONAL ANTIBODIES: A POTENTIAL ANTIGENIC DRIFT WITH AN IMPACT ON VACCINE EFFICACYANIMAL HEALTH TRUST, Newmarket, United Kingdom

P135 Seiya YamayoshiIDENTIFICATION OF AMINO ACIDS THAT ENHANCE VIRUS REPLICATION IN MAMMALIAN HOSTS IN THE PB2 AND PA PROTEINS OF A HIGHLY PATHOGENIC H7N9 INFLUENZA VIRUS ISOLATED FROM A HUMANINSTITUTE OF MEDICAL SCIENCE, UNIVERSITY OF TOKYO, Tokyo, Japan

P136 Joanna Pulit-PenalozaCOMPARATIVE IN VITRO AND IN VIVO ANALYSIS OF SWINE-ORIGIN H1N1 AND H1N2 INFLUENZA VIRUSES ISOLATED FROM HUMAN CASES BETWEEN 2011 AND 2016.CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States

P137 Tomoko FujiyukiONCOLYTIC RECOMBINANT MEASLES VIRUS IS A CANDIDATE THERAPEUTIC AGENT FOR REFRACTORY BREAST CANCERTHE UNIVERSITY OF TOKYO, Tokyo, Japan

P138 Stephanie ReynardSPECIFIC IMMUNOLOGICAL SIGNATURE DEPENDING ON THE DISEASE OUTCOME IN EBOLA VIRUS-INFECTED PATIENTS FROM MACENTA (GUINEA)INSTITUT PASTEUR, Lyon, France

P139 Shotaro UchidaMEASLES VIRUS V PROTEIN CONTRIBUTES TO THE TRANSPORT OF NUCLEOPROTEIN COMPLEXES AND EFFICIENT VIRAL ASSEMBLY IN NEURONAL CELLSJAPAN, Tokyo, Japan

P140 Kathleen CashmanEVIDENCE OF VIRAL PERSISTENCE IN CYNOMOLGUS MACAQUES THAT SURVIVE PARENTERAL EXPOSURE WITH LASSA FEVER VIRUSTHE GENEVA FOUNDATION / USAMRIID, Fort Detrick, United States

P141 Nicholas JohnsonIN SITU DEMONSTRATION OF RIFT VALLEY FEVER DISSEMINATION WITHIN CULEX PIPIENS MOSQUITOESAnimal and Plant Health Agency, Addlestone, United Kingdom

P142 Paul BrownEUROPEAN SUBGROUP C AVIAN METAPNEUMOVIRUS: PRELIMINARY EXPERIMENTAL INVESTIGATIONS ON THE ROLE OF THE SH PROTEIN IN PATHOGENICITY FOR MUSCOVY DUCKSANSES, Ploufragan, France

P143 Soner YildizINFLUENZA A VIRUS INFECTION PROMOTES LOCAL AND SYSTEMIC SUPER-INFECTION BY WEAKENING THE NATURAL SHIELD OF COMMENSAL BACTERIAUNIVERSITY OF GENEVA, CMU, Geneva, Switzerland

P144 Takeaki ImamuraAMINO ACID SUBSTITUTIONS IN THE PB2 PROTEIN OF AN H5N1 AVIAN INFLUENZA VIRUS ENHANCE ITS REPLICATION EFFICIENCY AND PATHOGENICITY IN MAMMALIAN HOSTS.THE INSTITUTE O MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO, Tokyo, Japan

P145 Léa MeyerLOW-PATHOGENIC AVIAN INFLUENZA VIRUSES HIJACK HOST’S CENTRAL METABOLIC PATHWAYSINRA, Jouy-en-Josas, France

P146 Monika RottsteggeA DONOR-MATCHED HUMANIZED MOUSE MODEL REVEALS A CHIEF ROLE OF THE APC-T CELL INTERFACE IN EBOLA VIRUS DISEASEBernhard-Nocht-Institute, Hamburg, Germany

P147 Julia PortLYMPHOCYTE HOMING SIGNATURES IN ACUTE LASSA VIRUS INFECTIONBerhard Nocht Institut, Hamburg, Germany

P148 Anne-Marie Connolly-AndersenMMP9 ASSOCIATES WITH ENDOTHELIAL GLYCOCALYX DEGRADATION DURING HEMORRHAGIC FEVER WITH RENAL SYNDROMEUMEÅ UNIVERSITY, Umeå, Sweden

PP149 Amelina Andrea AlbornozHANTAVIRUS RECEPTORS EXPRESSION AND DISTRIBUTION IN A LETHAL PULMONARY SYNDROME ANIMAL MODELFUNDACIÓN CIENCIA Y VIDA, Santiago, Chile

P150 Romy KerberBIOMARKER ANALYSIS OF HUMAN EBOLA VIRUS DISEASE UNDERSCORES THE ROLE OF TISSUE INTEGRITY IN SURVIVALBERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, Hamburg, Germany

P151 Misa KorvaCYTOKINE RESPONSE IN BUNYAVIRUS HEMORRHAGIC FEVERSUNIVERSITY OF LJUBLJANA, FACULTY OF MEDICINE, INSTITUTE OF MICROBIOLOGY AND IMMUNOLOGY, Ljubljana, Slovenia

P152 C ChevalierMOLECULAR CHARACTERIZATION OF PB1-F2-MEDIATED PATHOLOGY IN INFLUENZA MOUSE MODEL OF INFECTIONINRA, Jouy-en-Josas, France

P153 Linda RennickRECOMBINANT GENOTYPE G MUMPS VIRUS EXPRESSING ENHANCED GREEN FLUORESCENT PROTEIN EFFICIENTLY REPLICATES IN PRIMARY HUMAN CELLS AND IS VIRULENT IN COTTON RATSBOSTON UNIVERSITY, Boston, United States

P154 Pascale MassinTHE HIGHLY PATHOGENIC AVIAN INFLUENZA H5N1 A/CHICKEN/FRANCE/150169A/2015 PRESENTS IN VITRO PROPAGATION CHARACTERISTICS CONSISTENT WITH ITS PREDICTED TROPISM FOR AVIAN SPECIESANSES, Ploufragan, France

P155 Patrick SlaineADAPTIVE MUTATIONS IN INFLUENZA A/CALIFORNIA/07/2009 ENHANCE POLYMERASE ACTIVITY AND INFECTIOUS VIRION PRODUCTIONDALHOUSIE UNIVERSITY, Ridgeville, Canada

P156 Luca Zaeck3D IMAGING OF VIRUS INFECTIONS IN SOLVENT-CLEARED ORGANSFRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany

P157 Brigitta M LaksonoHUMAN B-CELLS ARE HIGHLY SUSCEPTIBLE TO IN VITRO AND IN VIVO MEASLES VIRUS INFECTIONERASMUS MC, Rotterdam, Netherlands

P158 Muneeswaran SelvarajUSE OF REVERSE GENETICS TECHNIQUE TO STUDY THE EARLY PATHOGENESIS OF PESTE DES PETITS RUMINANTS VIRUSTHE PIRBRIGHT INSTITUTE, Woking, United Kingdom

P159 Helena MüllerENTRY AND RELEASE OF LASSA VIRUS IN WELL-DIFFERENTIATED PRIMARY BRONCHIAL EPITHELIAL CELLSPHILIPPS UNIVERSITY MARBURG, Marburg, Germany

P160 Zachary BornholdtTHE PAN-EBOLAVIRUS THERAPEUTIC COCKTAIL MBP134 DEMONSTRATES UNIVERSAL PROTECTION FROM PATHOGENIC EBOLAVIRUSES.MAPP BIOPHARMACEUTICAL, INC., San Diego, United States

P161 Connie SchmaljohnENHANCEMENT OF DNA VACCINES FOR EBOLA VIRUS WITH AN IMPROVED PLASMID DESIGNUSAMRIID, Frederick, United States

P162 Takeshi IchinoheTHE EFFECTS OF OUTSIDE TEMPERATURE IN THE INDUCTION OF ADAPTIVE IMMUNITY TO INFLUENZA VIRUS INFECTIONUNIVERSITY OF TOKYO, Tokyo, Japan

P163 WithdrawnP164 L Gubareva

INSIGHTS INTO ANTIGENICITY OF INFLUENZA A(H3N2) VIRUS, 2012-2018CDC, Atlanta, United States

P165 Thomas HoenenIDENTIFICATION OF ESSENTIAL HOST FACTORS FOR EBOLA VIRUS RNA SYNTHESIS USING A GENOME-WIDE siRNA SCREENFRIEDRICH-LOEFFLER-INSTITUT, Greifswald, Germany

P166 Irina LenevaCHARACTERIZATION OF INFLUENZA VIRUS CLINICAL ISOLATES OBTAINED DURING UMIFENOVIR CLINICAL STUDY “ARBITR”FEDERAL STATE BUDGETARY SCIENTIFIC INSTITUTIONI.MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA, Moscow, Russian Federation

P167 Allison GrosethDEVELOPMENT AND APPLICATION OF ARENAVIRUS LIFECYCLE MODELLING SYSTEMSFRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany

P168 Hui-Wen ChenVACUOLAR ATPASE INHIBITING NANOPARTICLES EXHIBIT POTENT HOST-TARGETED ANTIVIRAL ACTIVITY AGAINST INFLUENZA VIRUSESNational Taiwan University, Taipei, Taiwan

P169 Christopher Donald RichardsonA VSV-MEASLES CHIMERIC VIRUS CAN TARGET NECTIN-4 POSITIVE BREAST CANCER TUMORS IN AN IMMUNE COMPETENT MOUSE AND IS ENHANCED BY TRANSIENT INHIBITION OF ANTI-VIRAL INNATE IMMUNITYDALHOUSIE UNIVERSITY, Halifax, Canada

P170 Michael TengENHANCING THE IMMUNOGENICITY AND ATTENUATION OF RESPIRATORY SYNCYTIAL VIRUS VACCINE CANDIDATES BY ALTERING NS1 FUNCTIONUNIVERSITY OF SOUTH FLORIDA, Tampa, United States

P171 David HawmanFAVIPIRAVIR BUT NOT RIBAVIRIN IS EFFECTIVE AGAINST TWO STRAINS OF CRIMEAN CONGO HEMORRHAGIC FEVER IN MICENIH/NIAD, Hamilton, United States

P172 Markus KainulainenSCALABLE REPLICON-PARTICLE VACCINE PROTECTS AGAINST LETHAL LASSA VIRUS INFECTION IN THE GUINEA PIG MODELCenters for Disease Control and Prevention, Atlanta, United States

P173 Annelies LeemansREMOVAL OF THE N-GLYCOSYLATION SEQUON AT POSITION N116 LOCATED IN P27 OF THE RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN ELICITS ENHANCED ANTIBODY RESPONSES AFTER DNA IMMUNIZATIONUNIVERSITY OF ANTWERP, Wilrijk, Belgium

P174 Nicole EspyRIBAVIRIN HAS A DEMONSTRABLE EFFECT ON CRIMEAN-CONGO HEMORRHAGIC FEVER VIRAL POPULATIONS AND VIRAL LOAD DURING PATIENT TREATMENTUNITED STATES ARMY RESEARCH INSTITUTE OF INFECTIOUS DISEASES, Frederick, United States

P175 Victor OutlawDEVELOPMENT OF BROAD-SPECTRUM PEPTIDOMIMETIC INHIBITORS OF PARAMYXOVIRAL FUSIONUNIVERSITY OF WISCONSIN–MADISON, Madison, United States

P176 Alexandra KupkeCORRELATES OF PROTECTION OF A MVA-BASED VACCINE AGAINST EBOLA VIRUS IN A MOUSE MODELInstitute of Virology, Philipps University Marburg, Marburg, Germany

P177 Tomoko KuwaharaISOLATION OF EGG-ADAPTED INFLUENZA A(H3N2) VIRUS WITHOUT AMINO ACID SUBSTITUTIONS IN THE ANTIGENIC SITES OF ITS HEMAGGLUTININNational Institute of Infectious Diseases, Musashi-Murayama, Japan

P178 Felix KreherBEWARE OF THE STING: THE SUPERPOWER OF MOSQUITO-PRODUCED RIFT VALLEY FEVER VIRUSGLASGOW UNIVERSITY, Glasgow, United Kingdom

P179 Sarah Hulsey StubbsA VESICULAR STOMATITIS VIRUS RECOMBINANT EXPRESSING THE OROPOUCHE VIRUS GLYCOPROTEINS ELICITS A NEUTRALIZING ANTIBODY RESPONSE IN MICE.HARVARD MEDICAL SCHOOL, Boston, United States

P180 Emi TakashitaIN VITRO CHARACTERIZATION OF MULTIDRUG-RESISTANT INFLUENZA A(H1N1)PDM09 VIRUSES CARRYING A DUAL AMINO ACID SUBSTITUTION ASSOCIATED WITH REDUCED SUSCEPTIBILITY TO NEURAMINIDASE INHIBITORSNATIONAL INSTITUTE OF INFECTIOUS DISEASES, Tokyo, Japan

P181 Mathieu MateoONE-SHOT IMMUNIZATION USING A MEASLES/LASSA VACCINE FULLY PROTECTS CYNOMOLGUS MONKEYS AGAINST LASSA FEVERINSTITUT PASTEUR, LYON, France

P182 Sylvia RothenbergerIDENTIFICATION OF SMALL-MOLECULE VIRAL INHIBITORS TARGETING VARIOUS STAGES OF THE LIFE-CYCLE OF HANTAVIRUSESCENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV) AND UNIVERSITY OF LAUSANNE, Epalinges, Switzerland

P183 Xavier CarnecA VACCINE PLATFORM AGAINST ARENAVIRUSES BASED ON A RECOMBINANT HYPER-ATTENUATED MOPEIA VIRUS EXPRESSING HETEROLOGOUS GLYCOPROTEINSInstitut Pasteur, Lyon, France

P184 Rashid ManzoorMECHANISM OF ANTIVIRAL ACTIVITY OF AN M2 ECTODOMAIN-SPECIFIC MONOCLONAL ANTIBODY AGAINST INFLUENZA A VIRUSRESEARCH CENTER FOR ZOONOSIS CONTROL, HOKKAIDO UNIVERSITY, Sapporo, Japan

P185 Cyril Le NouenOPTIMIZATION OF THE CODON PAIR USAGE OF HUMAN RESPIRATORY SYNCYTIAL VIRUS INCREASES PROTEIN SYNTHESIS BUT PARADOXICALLY DECREASES IMMUNOGENICITYNIH/NIAID/LID, BETHESDA, United States

P186 Sameer AyazDEFECTIVE INTERFERING vRNA ARE PRESENT IN LIVE ATTENUATED INFLUENZA VACCINE BUT THEY ARE NOT A MAJORITY POPULATION AND DO NOT APPEAR TO DRIVE REDUCED VACCINE EFFECTIVENESS.ASTRAZENECA, Liverpool, United Kingdom

P187 Lauren ParkerHA STABILITY IS NOT THE SOLE DETERMINANT OF LIVE ATTENUATED INFLUENZA VACCINE EFFECTIVENESSMEDIMMUNE/ASTRAZENECA, Liverpool, United Kingdom

P188 Nicolas EscriouLIVE RECOMBINANT MEASLES-M2 VACCINE CANDIDATES INDUCE BROAD-SPECTRUM PROTECTIVE IMMUNITY AGAINST INFLUENZA VIRUSES,INSTITUT PASTEUR, Paris, France

P189 Roland ZahnTHE ADENOVIRAL VECTOR AD26 EXPRESSING THE PREFUSION F PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS SHOWS HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE IN PRECLINICAL MODELS AS A PREREQUISITE FOR VACCINE DEVELOPMENT FOR YOUNG INFANTSJanssen Vaccines & Prevention, Leiden, Netherlands

P190 Aaron GingerichHYPOTHIOCYANITE DECREASES INFECTIVITY OF INFLUENZA A AND B VIRUSES INDEPENDENT OF NEURAMINIDASE ACTIVITY SUGGESTING A NOVEL MECHANISM OF VIRAL INACTIVATIONUNIVERSITY OF GEORGIA, Athens, United States

P191 Elizabeth AllenMOLECULAR BASIS OF ANTIBODY-MEDIATED NEUTRALIZATION REVEALS AN IMMUNODOMINANT SITE OF VULNERABILITY ON THE PHLEBOVIRAL SURFACEDIVISION OF STRUCTURAL BIOLOGY, UNIVERSITY OF OXFORD, Oxford, United Kingdom

P192 Maria Cristina Huertas-DiazRESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINES BASED ON PARAINFLUENZA VIRUS 5 (PIV5) AMPLIFYING VIRUS-LIKE PARTICLES PROTECT MICE AGAINST RSV CHALLENGEUNIVERSITY OF GEORGIA, Athens, United States

P193 Liang YeIFN-LAMBDA ACTS AS MUCOSAL ADJUVANT STRONGLY PROMOTING TSLP-MEDIATED IgG1 AND IgA ANTIBODY RESPONSESINSTITUTE OF VIROLOGY, UNIVERSITY MEDICAL CENTER FREIBURG, Freiburg, Germany

P194 Dorien De VliegerBISPECIFIC FC GAMMA RECEPTOR ENGAGING MOLECULES PROTECT AGAINST INFLUENZA A VIRUS INFECTIONSVIB-UGhent Center for Medical Biotechnology, Ghent, Belgium

P195 Anzhong LiA NOVEL METHYLTRANSFERASE-DEFECTIVE RECOMBINANT VESICULAR STOMATITIS VIRUS-BASED ZIKA VIRUS VACCINE EXPRESSING PRE-MEMBRANE, ENVELOPE AND NS1 PROTEINTHE OHIO STATE UNIVERSITY, Columbus, United States

P196 Prerna AroraIDENTIFICATION OF DETERMINANTS THAT CONTROL ANTIVIRAL ACTIVITY OF DEFECTIVE INTERFERING PARTICLES (DIP) AND GENERATION OF TOOLS FOR DIP PRODUCTIONDEUTSCHES PRIMATENZENTRUM GMBH LEIBNIZ-INSTITUT FÜR PRIMATENFORSCHUNG, GOETTINGEN, Germany

P197 Peter Luc DelputteRESPIRATORY SYNCYTIAL VIRUS (RSV) ENTRY IS INHIBITED BY SERINE PROTEASE INHIBITOR AEBSF WHEN PRESENT DURING EARLY STAGE INFECTIONUNIVERSITY OF ANTWERP, Antwerpen, Belgium

P198 Sandra DiederichHENIPAVIRUS-LIKE PARTICLES INDUCE BOTH HUMORAL AND CELL-MEDIATED IMMUNE RESPONSE IN PIGSFRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany

P199 Ronan Nicolas RouxelUNIVERSAL INFLUENZA VIRUS VACCINE: TWO DOSES OF ADJUVANTED CHIMERIC HEMAGGLUTININ INDUCE A STALK-SPECIFIC PROTECTIVE ANTIBODY RESPONSE AGAINST INFLUENZA VIRUS IN PRIMED ANIMALSGSK, Rixensart, Belgium

P200 Dirk RoymansTHERAPEUTIC EFFICACY OF A RESPIRATORY SYNCYTIAL VIRUS FUSION INHIBITORJanssen Infectious Diseases, Beerse, Belgium

P201 Yaiza Fernández GarcíaINCLUSION OF ANDES VIRUS CAP-SNATCHING ENDONUCLEASE IN THE SEARCH FOR NOVEL ANTIVIRALSBERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, Hamburg, Germany

P202 Kore SchlottauANTIVIRAL ACTIVITY OF RIBAVIRIN AND FAVIPIRAVIR AGAINST VARIEGATED SQUIRREL BORNAVIRUS 1FRIEDRICH-LOEFFLER-INSTITUT, Greifswald – Riems, Germany

P203 Ruth WatkinsonDEVELOPMENT OF A TEMPERATURE SENSITIVE, INTERFERON-SILENT SENDAI VIRUS FOR DELIVERY OF CRISPR/CAS9 FOR HIGHLY EFFICIENT GENE EDITING IN HEMATOPOIETIC STEM CELLSICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States

P204 James KellyCREATION OF A HIGH THROUGHPUT FUSION ASSAY TO SCREEN RSV INHIBITORSTHE PIRBRIGHT INSTITUTE, Woking, United Kingdom

P205 Stefanie A KrummELICITATION OF NEUTRALIZING ANTIBODIES AGAINST RVFV USING A RECOMBINANT Gn GLYCOPROTEIN.KING'S COLLEGE LONDON, London, United Kingdom

P206 Stéphanie AnchisiHDAC6, A NOVEL HOST TARGET FOR BROAD SPECTRUM ANTIVIRAL THERAPYFaculty of medicine, University of Geneva, Genève, Switzerland

P207 Svetlana ShcherbikANALYSIS OF STABILITY OF LAIV REASSORTANTS BASED ON A/LENINGRAD/134/17/57 CDC/NCRID, Atlanta, United States

P208 Hitoshi TakahashiESTABLISHMENT OF THE CROSS-CLADE ANTIGEN DETECTION SYSTEM FOR H5 SUBTYPE INFLUENZA VIRUSES USING PEPTIDE MONOCLONAL ANTIBODIES SPECIFIC FOR INFLUENZA VIRUS H5 HEMAGGLUTININNATIONAL INSTITUTE OF INFECTIOUS DISEASES, Musashimurayama, Japan

P209 Reiko YoshidaANTIVIRAL EFFECTS OF MONOCLONAL ANTIBODIES TARGETING H5N1 INFLUENZA VIRUS HEMAGGLUTININHOKKAIDO UNIVERSITY, Sapporo, Japan

P210 Punya RanjanSTATINS SUPPRESS EBOLA VIRUS INFECTIVITY BY INTERFERING WITH GLYCOPROTEIN PROCESSINGCENTER FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States

P211 Misako YonedaIMMUNE INDUCTABILITY OF RECOMBINANT MEASLES VIRUS VACCINES AGAINS NIPAH VIRUS INFECTION.THE UNIVERSITY OF TOKYO, Tokyo, Japan

P212 Oscar NegreteCRISPR SCREENS TARGETING VIRAL AND HOST GENOMES FOR ANTI-VIRAL COUNTERMEASURE DEVELOPMENTSANDIA NATIONAL LABORATORIES, Livermore, United States

P213 Sibylle HaidLABYRINTHOPEPTIN A1 AND A2 EFFICIENTLY INHIBIT CELL ENTRY OF HUMAN RESPIRATORY SYNCYTIAL VIRUS IN VITRO AND IN VIVOTWINCORE-CENTRE FOR EXPERIMENTAL AND CLINICAL INFECTION RESEARCH, Hannover, Germany

P214 J. Maximilian FelsNEUTRALIZING ANTIBODIES AGAINST CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS DERIVED FROM A HUMAN SURVIVORALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States

P215 Yasunori WatanabeSTRUCTURE OF LASSA VIRUS GLYCAN SHIELD PROVIDES A MODEL FOR IMMUNOLOGICAL RESISTANCEUNIVERSITY OF SOUTHAMPTON, Oxford, United Kingdom

P216 Miaoge XueRATIONAL DESIGN OF HUMAN RESPIRATORY SYNCYTIAL VIRUS LIVE ATTENUATED VACCINES BY INHIBITING VIRAL mRNA CAP METHYLTRANSFERASESTHE OHIO STATE UNIVERSITY, Columbus, United States

P217 Manon LaporteINHIBITION OF INFLUENZA- AND CORONAVIRUSES BY 1,4,4- TRISUBSTITUTED PIPERIDINESKU Leuven, Leuven, Belgium

P218 Victoria AvanzatoFLEXIBLE BAT IgG Fc QUATERNARY STRUCTURE PRESENTS ORDERED AND UNDER-PROCESSED GLYCANSUniversity of Oxford, Oxford, United Kingdom

EMERGING AND EVOLVING

P219 Danielle AndersonCOMPARATIVE LOSS-OF-FUNCTION SCREENS HIGHLIGHT COMMON CELLULAR PATHWAYS REQUIRED BY MUMPS VIRUS FOR REPLICATION IN BATS AND HUMANSDUKE-NUS MEDICAL SCHOOL, Singapore, Singapore

P220 Hong JinMOLECULAR ANALYSIS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) F AND G PROTEINS DURING THE 2015-2017 WINTER SEASONS IN THE US AND VIRAL SUSCEPTIBILITY TO ANTI-RSV MABSMEDIMMUNE, South San Francisco, United States

P221 Mifang LiangEPIDEMIOLOGICAL INVESTIGATION AND MOLECULAR EVOLUTION OF SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROMENATIONAL INSTITUTE FOR VIRAL DISEASES CONTROL AND PREVENTION，CHINA CDC, Beijing, China

P222 Bertus RimaSTRANGE STABLE REPLICATORS GENERATED FROM MUMPS VIRUS CDNA CLONES.QUEEN'S UNIVERSITY BELFAST, Belfast, United Kingdom

P223 Randal SchoeppEVIDENCE FOR CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS IN MONGOLIAUSAMRIID, Fort Detrick, United States

P224 Tony SchountzTRANSMISSION OF RESCUED BAT HL18NL11 INFLUENZA A-LIKE VIRUS IN EXPERIMENTALLY-INFECTED JAMAICAN FRUIT BATSCOLORADO STATE UNIVERSITY, Fort Collins, United States

P225 Samantha KasloffPATHOGENICITY OF NIPAH VIRUS BANGLADESH IN EXPERIMENTALLY INFECTED PIGSCanadian Food Inspection Agency, National Centre for Foreign Animal Disease, WINNIPEG, Canada

P226 Yasuha AraiGENETIC COMPATIBILITY AND VIRULENCE OF REASSORTANTS DERIVED FROM H9N2 AND H5N1 AVIAN INFLUENZA VIRUSES CO-CIRCULATING IN EGYPTKYOTO PREFECTURAL SCHOOL OF MEDICINE, Kyotoーshi, Japan

P227 Won-Keun KimMULTIPLEX PCR-BASED NEXT-GENERATION SEQUENCING OF HANTAVIRUSES IN HUMANS AND RODENTSKOREA UNIVERSITY COLLEGE OF MEDICINE, Seoul, Korea, Republic Of

P228 Carles Martínez-RomeroPHENOTYPIC EVOLUTION OF NEURAMINIDASE OF INFLUENZA A(H1N1)PDM09 VIRUSICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States

P229 Julia DinaIDENTIFICATION OF MUTATIONS IN GENES CODING FOR SURFACE F AND G PROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS ISOLATED FROM CHILDREN TREATED WITH PALIVIZUMABUNIVERSITY HOSPITAL OF CAEN, Caen, France

P230 Jens KuhnMEGATAXONOMY OF NEGATIVE-SENSE RNA VIRUSES: PHYLUM "NEGARNAVIRICOTA" NIH/NIAID/DCR/INTEGRATED RESEARCH FACILITY AT FORT DETRICK, Frederick, United States

P231 Melle HolwerdaANALYSIS OF THE ZOONOTIC POTENTIAL OF INFLUENZA D VIRUS FOR HUMANSInstitute for Virology and Immunology IVI, Bern, Switzerland

P232 Helene SchulzBAYESIAN EVOLUTIONARY ANALYSIS BY SAMPLING TREES APPLIED TO EXTENDED SEQUENCING OF MEASLES VIRUS FOR MOLECULAR EPIDEMIOLOGY OF OUTBREAKS.PUBLIC HEALTH AGENCY OF CANADA, Winnipeg, Canada

P233 Mifang LiangSEROLOGICAL INVESTIGATIONS OF LABORATORY-CONFIRMED AND SUSPECTED EBOLA PATIENTS DURING THE LATE PHASE OF THE EBOLA OUTBREAK IN SIERRA LEONENATIONAL INSTITUTE FOR VIRAL DISEASES CONTROL AND PREVENTION，CHINA CDC, Beijing, China

P234 Gvantsa ChanturiaDETECTION OF HANTAVIRUS RNA IN HUMAN SAMPLES IN GEORGIANATIONAL CENTER FOR DISEASE CONTROL AND PUBLIC HEALTH OF GEORGIA (NCDC), Tbilisi, Georgia

P235 Suxiang TongGENOMIC CHARACTERIZATION OF VIRUSES IN DROMEDARY CAMELS FROM UNITED ARAB EMIRATESCDC, Atlanta, United States

P236 Rainer G. UlrichMOLECULAR DETECTION OF PUUMALA ORTHOHANTAVIRUS: STRUGGLING WITH HIGH NUCLEOTIDE SEQUENCE VARIABILITYFRIEDRICH-LOEFFLER-INSTITUT, Greifswald-Insel Riems, Germany

P237 Masayuki HorieSYSTEMATIC INVESTIGATION OF NOVEL LINEAGES OF ENDOGENOUS BORNAVIRUS-LIKE ELEMENTS IN VERTEBRATE GENOMESKYOTO UNIVERSITY, Kyoto, Japan

P238 Laura BehnerFUNCTIONAL KUMASI VIRUS SURFACE GLYCOPROTEIN G IS EXPRESSED IN HIGH-ORDER OLIGOMERSPHILIPPS UNIVERSITY MARBURG, INSTITUTE OF VIROLOGY, Marburg, Germany

P239 Kerstin FischerSEROLOGICAL EVIDENCE FOR THE CIRCULATION OF EBOLAVIRUSES IN SWINE IN WEST AFRICAFRIEDRICH-LOEFFLER-INSTITUT; INSTITUTE OF NOVEL AND EMERGING INFECTIOUS DISEASESGreifswald - Insel Riems, Germany

P240 Masahiro KajiharaSEROLOGICAL AND MOLECULAR EVIDENCE FOR CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS CIRCULATION IN TICKS, CATTLE, AND HUMANS IN ZAMBIAHOKKAIDO UNIVERSITY, Sapporo, Japan

P241 U.G. LiebertREVERSE GENETICS PLATFORM FOR IMPROVED CLONING AND EFFICIENT RESCUE OF MEASLES VIRUS FROM CDNALEIPZIG UNIVERSITY, Leipzig, Germany

P242 Naganori NaoTHE CHARACTERISTICS OF RECENT CLINICAL ISOLATES OF HUMAN METAPNEUMOVIRUS IN JAPANNATIONAL INSTITUTE OF INFECTIOUS DISEASES, Musashimurayama city, Tokyo, Japan

P243 Roena SukhiashviliIDENTIFICATION OF NEW ENDEMIC REGION FOR CCHFV IN GEORGIANATIONAL CENTER FOR DISEASE CONTROL AND PUBLIC HEALTH (NCDC), Tbilisi, Georgia

P244 Yohei WatanabeCHARACTERIZATION OF H5N1 AVIAN INFLUENZA VIRUS QUASISPECIES WITH ADAPTIVE HEMAGGLUTININ MUTATIONS FROM SINGLE-VIRUS INFECTIONS OF HUMAN AIRWAY CELLSKYOTO PREFECTURAL UNIVERSITY OF MEDICINE, Kyoto, Japan

P245 Bo ShuDEVELOPMENT AND QUALIFICATION OF REAL-TIME RT-PCR ASSAYS FOR THE DETECTION AND DISCRIMINATION OF INFLUENZA B VICTORIA LINEAGE K162N163 DELETION VIRUSESCENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States

P246 Kai-Hui WuPERFORMANCE EVALUATION OF THE UPDATED CDC REAL-TIME RT-PCR INFLUENZA B LINEAGE GENOTYPING PANELCENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States

P247 Yohei KurosakiDIFFERENT EFFECTS OF TWO MUTATIONS ON THE INFECTIVITY OF EBOLA VIRUS GLYCOPROTEIN IN NINE MAMMALIAN SPECIESINSTITUTE OF TROPICAL MEDICINE, NAGASAKI UNIVERSITY, Nagasaki, Japan

P248 Alice StelfoxSTRUCTURAL BASIS FOR DIVERGENT RECEPTOR TROPISM OF EMERGING UNCLASSIFIED PARAMYXOVIRUSESUNIVERSITY OF OXFORD, Oxford, United Kingdom

P249 Noémie AurineSOMATIC REPROGRAMMING IN PTEROPUS BAT CELLS TO DEVELOP NEW MODEL TO STUDY HIGHLY PATHOGENIC VIRUSESINSERM, Villeurbanne, France

List of Participants

ABOU HAMDAN Abbas, CNRS, Gif Sur Yvettes, France - P013abbas.abou-hamdan@i2bc.paris-saclay.fr

AGUILAR-CARRENO Hector, CORNELL UNIVERSITY, Ithaca, United States - 8ha363@cornell.edu

AIT-GOUGHOULTE Malika, ROCHE, Basel, Switzerland malika.ait-goughoulte@roche.com

ALARCÓN Rodolfo, Bethesda, United States -rodolfo.alarcon@nih.gov

ALBERTINI Aurelie, CNRS, Gif Sur Yvette, France - 4, P013aurelie.albertini@cnrs.fr

ALBORNOZ Amelina, FUNDACIÓN CIENCIA Y VIDA, Santiago, Chile - P149aalbornoz@cienciavida.org

ALLEN Elizabeth, DIVISION OF STRUCTURAL BIOLOGY, UNIVERSITY OF OXFORD, Oxford, United Kingdom - P191, P205elizabeth.allen@ndm.ox.ac.uk

AMARASINGHE Gaya, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, St. Louis, United States - 50, P030gamarasinghe@wustl.edu

ANCHISI Stéphanie, FACULTY OF MEDICINE, UNIVERSITY OF GENEVA, Genève, Switzerland -P206Stephanie.Anchisi@unige.ch

ANDERSON Danielle, DUKE-NUS MEDICAL SCHOOL, Singapore, Singapore - 69, P219danielle.anderson@duke-nus.edu.sg

ANDREJEVA Jelena, UNIVERSITY OF ST. ANDREWS, SCOTLAND, UK, St. Andrews, United Kingdom - P072ja21@st-andrews.ac.uk

ANTHONY Simon, COLUMBIA UNIVERSITY, NYC, United Statessja2127@cumc.columbia.edu

ARAI Yasuha, KYOTO PREFECTURAL SCHOOL OF MEDICINE, Kyotoーshi, Japan - P226yarai@koto.kpu-m.ac.jp

ARNOLD Catherine, U.S ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES, Frederick, United States - P070catherine.e.arnold13.ctr@mail.mil

ARORA Prerna, DEUTSCHES PRIMATENZENTRUM GMBH LEIBNIZ-INSTITUT FÜR PRIMATENFORSCHUNG, Goettingen, Germany - P196parora@dpz.eu

AURINE Noémie, Villeurbanne, France - 88, P249noemie.aurine@inserm.fr

AVANZATO Victoria, UNIVERSITY OF OXFORD, Oxford, United Kingdom - P218victoria.avanzato@strubi.ox.ac.uk

AVENA Laura, San Antonio, United States -lavena@txbiomed.org

AVSIC ZUPANC Tatjana, UNIVERSITY OF LJUBLJANA, FACULTY OF MEDICINE, INSTITUTE OF MICROBIOLOGY AND IMMUNOLOGY, Ljubljana, Slovenia - P150, P151tatjana.avsic@mf.uni-lj.si

AYAZ Sameer, ASTRAZENECA, Liverpool, United Kingdom - P186ayazs@medimmune.com

AZARM Kristopher, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States - P009, P021kristopher.azarm@icahn.mssm.edu

BACH Simone, PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany - 18bachsi@staff.uni-marburg.de

BADHAM Matthew, UNIVERSITY OF KENT, Canterbury, United Kingdom - P116mb732@kent.ac.uk

BAILEY Dalan, THE PIRBRIGHT INSTITUTE, Guildford, United Kingdom - P003, P173, P204dalan.bailey@pirbright.ac.uk

BAILLET Nicolas, Lyon, France - P181nicolas.baillet@pasteur.fr

BAILLON Laury, INRA, Jouy En Josas, France - 28laury.baillon@inra.fr

BAIZE Sylvain, INSTITUT PASTEUR, Lyon Cedex 7, France - P138, P181, P183sylvain.baize@pasteur.fr

BAKKERS Mark, HARVARD MEDICAL SCHOOL, Boston, United States - P016mark_bakkers@hms.harvard.edu

BARCLAY Wendy, IMPERIAL COLLEGE, London, United Kingdom - 20, 71, P091w.barclay@imperial.ac.uk

BASLER Christopher, GEORGIA STATE UNIVERSITY, Atlanta, United States - 17, P073cbasler@gsu.edu

BAUER David, UNIVERSITY OF OXFORD, Oxford, United Kingdom - 66, P056, P066, P115david.bauer@path.ox.ac.uk

BECKER Stephan, INSTITUT FÜR VIROLOGIE, PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany - P193becker@staff.uni-marburg.de

BEHNER Laura, PHILIPPS UNIVERSITY MARBURG, INSTITUTE OF VIROLOGY, Marburg, Germany -P065, P110, P238behner@staff.uni-marburg.de

BELOT Laura, I2BC, Gif-Sur-Yvette, France - 4, P013laura.belot@i2bc.paris-saclay.fr

BENTON Donald, THE FRANCIS CRICK INSTITUTE, London, United Kingdom - 3donald.benton@crick.ac.uk

BERTRAN Andre, LABORATORY OF VIROLOGY, WAGENINGEN UNIVERSITY, Wageningen, Netherlands - P046andre.bertran@wur.nl

BEURET Christian, SPIEZ LABORATORY, Spiez, Switzerlandchristian.beuret@babs.admin.ch

BIACCHESI Stephane, INRA, Jouy En Josas, France - 28stephane.biacchesi@inra.fr

BIEDENKOPF Nadine, PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany - 18, P036, P047nadine.biedenkopf@staff.uni-marburg.de

BLOYET Louis-Marie, HARVARD MEDICAL SCHOOL, Boston, United States - 24, 88, P038, P058louis-marie_bloyet@hms.harvard.edu

BOGDANOW Boris, MDC BERLIN, Berlin, Germany - P059boris.bogdanow@mdc-berlin.de

BOON Jacco, WASHINGTON UNIVERSITY, Saint Louis, United States - 19, 50jboon@wustl.edu

List of ParticipantsBÖRGELING Yvonne, UNIVERSITY OF MUENSTER, Münster, Germany - P111borgelin@uni-muenster.de

BORNHOLDT Zachary, MAPP BIOPHARMACEUTICAL, INC., San Diego, United States - P160, P214zachary.bornholdt@mappbio.com

BOTTEN Jason, UNIVERSITY OF VERMONT, Burlington, United States - 47, 48, P112jbotten@uvm.edu

BOURHIS Jean-Marie, INSTITUT DE BIOLOGIE STRUTURALE, Grenoble, France - P026jean-marie.bourhis@ibs.fr

BOWDEN Thomas, UNIVERSITY OF OXFORD, Oxford, United Kingdom - 10, 74, P009, P018, P019, P021, P205, P191, P215, P218, P248tom@strubi.ox.ac.uk

BREMONT Michel, INRA, Jouy En Josas, France -28michel.bremont@jouy.inra.fr

BRENNAN Benjamin, MRC-UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH, Glasgow, United Kingdom - P191ben.brennan@glasgow.ac.uk

BROOKE Chris, UNIVERSITY OF ILLINOIS, Urbana, United States - 26cbrooke@illinois.edu

BROWN Paul, ANSES, Ploufragan, France - P142paul.brown@anses.fr

BRUCE Emily, UNIVERSITY OF VERMONT, Burlington, United States - 47embruce@gmail.com

BRUCHEZ Anna, BENAROYA RESEARCH INSTITUTE, Seattle, United States - P071abruchez@benaroyaresearch.org

BRUNOTTE Linda, UNIVERSITY OF MUENSTER, Muenster, Germany - 35brunotte@uni-muenster.de

BUCHHOLZ Ulla, NIAID, NIH, Bethesda, United States - 79, 91, P185ubuchholz@niaid.nih.gov

BUKREYEV Alexander, UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON, GALVESTON NATIONAL LABORATORY, Galveston, United States - 32abukreye@utmb.edu

BYRD-LEOTIS Lauren, HARVARD MEDICAL SCHOOL, Boston, United States - P004labyrd@bidmc.harvard.edu

CALDER Lesley, THE FRANCIS CRICK INSTITUTE, London, United Kingdom - 3Lesley.Calder@crick.ac.uk

CANTONI Diego, UNIVERSITY OF KENT, Canterbury, United Kingdom - P081dmc33@kent.ac.uk

CARDONE Christophe, CNRS ICSN, Gif-Sur-Yvette Cedex, France - P027, P055christophe.cardone@cnrs.fr

CARNEC Xavier, INSTITUT PASTEUR, Lyon, France - P181, P183xavier.carnec@pasteur.fr

CARRIQUE Loic, UNIVERSITY OF OXFORD, Oxford, United Kingdomloic@strubi.ox.ac.uk

CASHMAN Kathleen, THE GENEVA FOUNDATION / USAMRIID, Fort Detrick, United States - P140kathleen.a.cashman.ctr@mail.mil

CATTANEO Roberto, MAYO CLINIC, Rochester, United States - 2, 25, P067cattaneo.roberto@mayo.edu

CHANDA Sumit, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSITUTE, La Jolla, United States - P068, P069schanda@sbpdiscovery.org

CHANDRAN Kartik, ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States - 5, 6, P006, P017, P160, P214kartik.chandran@gmail.com

CHANTURIA Gvantsa, NATIONAL CENTER FOR DISEASE CONTROL AND PUBLIC HEALTH OF GEORGIA (NCDC), Tbilisi, Georgia - P234, P243gvantsa.chanturia@ncdc.ge

CHEN Hui-Wen, NATIONAL TAIWAN UNIVERSITY, Taipei, Taiwan - P168winnichen@ntu.edu.tw

CHEVALIER Christophe, INRA, Jouy-En-Josas, France - P152christophe.chevalier@inra.fr

CIMINSKI Kevin, UNIVERSITY MEDICAL CENTER FREIBURG CENTER FOR MICROBIOLOGY AND HYGIENE INSTITUTE OF VIROLOGY, Freiburg, Germany - 1, 90kevin.ciminski@uniklinik-freiburg.de

CLOHISEY Sara, THE ROSLIN INSTITUTE, Edinburgh, United Kingdom - P076sara.clohisey@roslin.ed.ac.uk

COMPANS Richard, EMORY UNIVERSITY, Atlanta, United Statesrwcompans@yahoo.com

CONCEICAO Carina, THE ROSLIN INSTITUTE, UNIVERSITY OF EDINBURGH, Roslin, United Kingdom - P117s1581717@sms.ed.ac.uk

CONNOLLY-ANDERSEN Anne-Marie, UMEÅ UNIVERSITY, Umeå, Sweden - P148anne-marie.connolly-andersen@umu.se

CONZELMANN Karl-Klaus, LMU MUNICH, München, Germany - 27, P130conzelmann@genzentrum.lmu.de

COURRIER Alexis, UNIGE, Geneva, Switzerland -alexis.courrier@unige.ch

CREPIN Thibaut, IBS, UNIV. GRENOBLE ALPES, CEA, CNRS, Grenoble, France - P026thibaut.crepin@ibs.fr

CUSI Maria Grazia, UNIVERSITY OF SIENA, Siena, Italy - P092mariagrazia.cusi@unisi.it

DADONAITE Bernadeta, UNIVERSITY OF OXFORD, Oxford, United Kingdom - P115magd4203@nexus.ox.ac.uk

DE BOER Steffen Matthijn, INTRAVACC, Apeldoorn, Netherlands -matthijn.deboer@gmail.com

DE SWART Rik, ERASMUS MC, Rotterdam, Netherlands - 55, 60, P157r.deswart@erasmusmc.nl

DE VLIEGER Dorien, VIB-UGENT CENTER FOR MEDICAL BIOTECHNOLOGY , VIB, GHENT, BELGIUM, Zwijnaarde, Belgium - P194dorien.devlieger@vib-ugent.be

DELMAS Bernard, INRA, Jouy-En-Josas, France -P026, P040, P145, P152bernard.delmas@inra.fr

DELPUTTE Peter, UNIVERSITY OF ANTWERP, Antwerpen, Belgium - P173, P197peter.delputte@uantwerpen.be

DENG Tao, INSTITUTE OF PATHOGEN BIOLOGY,CHINESE ACADEMY OF MEDICAL SCIENCES, Beijing, China - P107taodeng303@163.com

DEVIGNOT Stéphanie, INSTITUTE FOR VIROLOGY, FB10 VETERINARY MEDICINE, Giessen, Germany - P089Stephanie.Devignot@vetmed.uni-giessen.de

List of ParticipantsDIBBEN Oliver, MEDIMMUNE, Liverpool, United Kingdom - 81, P186, P187dibbeno@medimmune.com

DIEDERICH Sandra, FRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany -P198, P239sandra.diederich@fli.de

DIJKMAN Ronald, INSTITUTE OF VIROLOGY AND IMMUNOLOGY IVI, Bern, Switzerland - 36, P061, P213, P231ronald.dijkman@vetsuisse.unibe.ch

DINA Julia, UNIVERSITY HOSPITAL OF CAEN, Caen, France - P229dina-j@chu-caen.fr

DOLNIK Olga, PHILIPPS-UNIVERSITY MARBURG, Marburg, Germany - P113dolnik@staff.uni-marburg.de

DONOHUE Ryan, MAYO CLINIC, Rochester, United States - 2, 25Donohue.Ryan@mayo.edu

DOORES Katie, KING'S COLLEGE LONDON, London, United Kingdom - 74, P191, P205katie.doores@kcl.ac.uk

DUPREX Paul, BOSTON UNIVERSITY SCHOOL OF MEDICINE, Boston, United States - 55, P049, P153, P213, P219, P222pduprex@bu.edu

DUTCH Rebecca, UNIVERSITY OF KENTUCKY, Lexington, United States - 7rdutc2@uky.edu

EATON Brett, US ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES, Frederick, United Statesbrett.eaton1@us.army.mil

EDWARDS Megan, GEORGIA STATE UNIVERSITY, Atlanta, United States - P073medwards38@gsu.edu

ELEOUET Jean-Francois, INRA, Jouy En Josas, France - P027, P028, P039, P051, P055, P213jean-francois.eleouet@inra.fr

ESCRIOU Nicolas, INSTITUT PASTEUR, Paris, France - P188nicolas.escriou@pasteur.fr

ESPY Nicole, UNITED STATES ARMY RESEARCH INSTITUTE OF INFECTIOUS DISEASES, Frederick, United States - P174nicole.espy@gmail.com

FALCON Ana, CENTER FO BIOMEDICAL RESEARCH (CIBER), Madrid, Spain - 33, 65afalcon@cnb.csic.es

FAN Haitian, UNIVERSITY OF OXFORD, Oxford, United Kingdom - 14, P056haitian.fan@path.ox.ac.uk

FAY Elizabeth, UNIVERSITY OF MINNESOTA, Minneapolis, United States - 42fayxx084@umn.edu

FEARNS Rachel, BOSTON UNIVERSITY SCHOOL OF MEDICINE, Boston, United States - 22rfearns@bu.edu

FEDELI Chiara, LAUSANNE UNIVERSITY HOSPITAL, Lausanne, Switzerland - 11Chiara.Fedeli@chuv.ch

FEHLING Sarah, PHILIPPS UNIVERSITY MARBURG, Marburg, Germany - P118, P159fehling@staff.uni-marburg.de

FELS J. Maximilian, ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States - 6, P214max.fels@phd.einstein.yu.edu

FERNÁNDEZ GARCÍA Yaiza, BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, Hamburg, Germany - P201fernandez-garcia@bnitm.de

FIEGE Jessica, UNIVERSITY OF MINNESOTA, Minneapolis, United States - 42, 58fiege018@umn.edu

FINKE Stefan, FRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany - 49, P121, P156, P165stefan.finke@fli.de

FISCHER Kerstin, FRIEDRICH-LOEFFLER-INSTITUT; INSTITUTE OF NOVEL AND EMERGING INFECTIOUS DISEASES, Greifswald - Insel Riems, Germany - P239kerstin.fischer@fli.de

FODOR Ervin, UNIVERSITY OF OXFORD, Oxford, United Kingdom - 14, 66, P023, P034, P056, P066, P115ervin.fodor@path.ox.ac.uk

FUJIYUKI Tomoko, THE UNIVERSITY OF TOKYO, Tokyo, Japan - P124, P137fujiyuki@ims.u-tokyo.ac.jp

GAGLIA Marta, TUFTS UNIVERSITY SCHOOL OF MEDICINE, Boston, United States - 34Marta.Gaglia@tufts.edu

GALAO Rui, KING'S COLLEGE LONDON, London, United Kingdom - 39, P075rui_pedro.galao@kcl.ac.uk

GANDOLFO Claudia, UNIVERSITY OF SIENA, Colle Di Val D'Elsa, Italy - P092gandolfo@unisi.it

GARCÍA-SASTRE Adolfo, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States - 1, 19, 30, P068, P069, P108, P228adolfo.garcia-sastre@mssm.edu

GARCIN Dominique, UNIVERSITY OF GENEVA, Geneva, Switzerland - 56dominique.garcin@unige.ch

GAST Matthieu, UNIVERSITY OF BERN VETUISSE FACULTY, Bern, Switzerland - P122, P123matthieu.gast@vetsuisse.unibe.ch

GAUDIN Yves, INSTITUT DE BIOLOGIE INTÉGRATIVE DE LA CELLULE, CNRS, Gif Sur Yvette, France - 4, 46, P013yves.gaudin@i2bc.paris-saclay.fr

GERLIER Denis, CIRI INSERM U1111, CNRS UMR5307, UNIVERSITY LYON 1, ENS LYON, UNIV LYON, Lyon, France - 88, P038, P058denis.gerlier@inserm.fr

GHANEM Alexander, LMU MUNICH, Munich, Germany - P130ghanem@genzentrum.lmu.de

GIAVEDONI Luis, TEXAS BIOMEDICAL RESEARCH INSTITUTE, San Antonio, United States lgiavedoni@txbiomed.org

GINGERICH Aaron, UNIVERSITY OF GEORGIA, Athens, United States - P190adgingerich@gmail.com

GOLDHILL Daniel, IMPERIAL COLLEGE, London, United Kingdom - 71d.goldhill@imperial.ac.uk

GOUJON Caroline, INSTITUT DE RECHERCHE EN INFECTIOLOGIE DE MONTPELLIER (IRIM), CNRS / MONTPELLIER UNIVERSITY, Montpellier, France - 37, P091caroline.goujon@irim.cnrs.fr

GOULD Joseph, UNIVERSITY OF ALABAMA AT BIRMINGHAM, Birmingham, United States -P057jgould@uab.edu

GOVORKOVA Elena, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, United States -elena.govorkova@stjude.org

GREEN Todd, Birmingham, United States - P057tgreen@uab.edu

List of ParticipantsGRIFFIN Diane, JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH, Hunt Valley, United States - 83dgriffi6@jhu.edu

GRIFFITHS Anthony, TEXAS BIOMED, San Antonio, United States - 59, P054agriffiths@Txbiomed.org

GROSETH Allison, FRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany -P165, P167allison.groseth@fli.de

GUBAREVA Larisa, CDC, Atlanta, United States -P164ISY7@CDC.GOV

GUITO Jonathan, CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States - P070pobfligopsctc@gmail.com

GÜNTHER Maria, FRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany -P121maria.guenther@fli.de

HAID Sibylle, TWINCORE- CENTRE FOR EXPERIMENTAL AND CLINICAL INFECTION RESEARCH, Hannover, Germany - 62, P020, P213sibylle.haid@twincore.de

HALE Benjamin, UNIVERSITY OF ZURICH, Zurich, Switzerland - 1hale.ben@virology.uzh.ch

HALLER Otto, INSTITUTE OF VIROLOGY, MEDICAL CENTER - UNIVERSITY OF FREIBURG, GERMANY, Zürich, Switzerlandotto.haller@uniklinik-freiburg.de

HAN Julianna, THE UNIVERSITY OF CHICAGO, Chicago, United States - P078juliannahan@uchicago.edu

HARA Koyu, KURUME UNIVERSITY SCHOOL OF MEDICINE, Kurume, Japan - P052koyu@med.kurume-u.ac.jp

HARMON Brooke, Livermore, United States -P132, P172bharmon@sandia.gov

HARTMAN Amy, UNIVERSITY OF PITTSBURGH, Pittsburgh, United States - 64, P125hartman2@pitt.edu

HAWMAN David, NIH/NIAD, Hamilton, United States - P171david.hawman@nih.gov

HENNRICH Alexandru Adrian, LMU MÜNCHEN, Munich, Germany - P130hennrich@genzentrum.lmu.de

HERREN Michael, UNIVERSITY OF BERN, Bern, Switzerland - P011michael.herren@vetsuisse.unibe.ch

HERRLER Georg, STIFTUNG TIERÄRZTLICHE HOCHSCHULE HANNOVER, Hannover, Germany -P015, P064, P127Georg.Herrler@tiho-hannover.de

HERSCHKE Florence, JANSSEN PHARMACEUTICA NV, Beerse, Belgium fherschk@its.jnj.com

HERZOG Norbert, FRANK H. NETTER SCHOOL OF MEDICINE, Guilford, United States -docnh@msn.com

HOENEN Thomas, FRIEDRICH-LOEFFLER-INSTITUT, Greifswald, Germany - P165, P167, P239thomas.hoenen@fli.de

HOFFMANN Markus, DEUTSCHES PRIMATENZENTRUM GMBH, LEIBNIZ-INSTITUT FÜR PRIMATENFORSCHUNG, Göttingen, Germany - P093MHoffmann@dpz.eu

HOLWERDA Melle, INSTITUTE FOR VIROLOGY AND IMMUNOLOGY IVI, Bern, Switzerland -P061, P231melle.holwerda@vetsuisse.unibe.ch

HONDA Tomoyuki, OSAKA UNIVERISTY, Osaka, Japan - P098thonda@virus.med.osaka-u.ac.jp

HOOPER Jay, Fort Detrick, United States - P149jay.w.hooper.civ@mail.mil

HORIE Masayuki, KYOTO UNIVERSITY, Kyoto, Japan - P044, P105, P237horie.masayuki.3m@kyoto-u.ac.jp

HORVAT Branka, CIRI, Lyon, France - 88, P249branka.horvat@inserm.fr

HORWITZ Joshua, HARVARD MEDICAL SCHOOL, Boston, United States - P050jhorwitz@crystal.harvard.edu

HUA Brian, CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States - 40, P131 - brianlhua@gmail.com

HUERTAS-DIAZ Maria, UNIVERSITY OF GEORGIA, Athens, United States - P192mhuertas@uga.edu

HULSEY STUBBS Sarah, HARVARD MEDICAL SCHOOL, Boston, United States - P016, P179sarah_stubbs@hms.harvard.edu

HUTCHINSON Edward, MRC-UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH, Glasgow, United Kingdom - 43, P023, P032edward.hutchinson@glasgow.ac.uk

ICHINOHE Takeshi, UNIVERSITY OF TOKYO, Tokyo, Japan - P080, P086, P162ichinohe@ims.u-tokyo.ac.jp

IKEDA Fusako, THE UNIVERSITY OF TOKYO, Tokyo, Japan - P096, P139s-fusako@ims.u-tokyo.ac.jp

IMAMURA Takeaki, THE INSTITUTE O MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO, Tokyo, Japan - P144timamura@ims.u-tokyo.ac.jp

IRIE Takashi, HIROSHIMA UNIVERSITY, Hiroshima, Japan - P120tirie@hiroshima-u.ac.jp

JANGRA Rohit, ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States - 5, 6, P006, P017rohit.jangra@einstein.yu.edu

JIN Hong, MEDIMMUNE, South San Francisco, United States - P220jinh@medimmune.com

JOHNSON Nicholas, ANIMAL AND PLANT HEALTH AGENCY, Addlestone, United Kingdom -P141Nick.Johnson@apha.gsi.gov.uk

JOHNSON Rebecca, CSIRO-AUSTRALIAN ANIMAL HEALTH LABORATORY, East Geelong, Australia -86rebecca.johnson@csiro.au

JONSSON Colleen, UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER, Memphis, United States - P085cjonsson@uthsc.edu

KADZIOCH Nicole, UNIVERSITY OF BERN, VETSUISSE FACULTY, Bern, Switzerland - P122, P123nicole.kadzioch@vetsuisse.unibe.ch

KAI Chieko, THE UNIVERSITY OF TOKYO, Tokyo, Japan - P053, P090, P096, P124, P137, P139, P211ckai@ims.u-tokyo.ac.jp

KAINULAINEN Markus, CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States - P172ydm9@cdc.gov

List of ParticipantsKAJIHARA Masahiro, HOKKAIDO UNIVERSITY, Sapporo, Japan - P240kajihara@czc.hokudai.ac.jp

KARAKUS Umut, UNIVERSITY OF ZURICH, INSTITUTE OF MEDICAL VIROLOGY, Zurich, Switzerland - 1karakus.umut@virology.uzh.ch

KASLOFF Samantha, CANADIAN FOOD INSPECTION AGENCY, NATIONAL CENTRE FOR FOREIGN ANIMAL DISEASE, Winnipeg, Canada -P225 - samantha.kasloff@gmail.com

KATZ Aliza, WEIZMANN INSTITUTE, Jerusalem, Israel – 82 - aliza.katz@weizmann.ac.il

KAWAGUCHI Atsushi, UNIVERSITY OF TSUKUBA, Tsukuba, Japan - P060, P101ats-kawaguchi@md.tsukuba.ac.jp

KELLY James, THE PIRBRIGHT INSTITUTE, Woking, United Kingdom - P204james.kelly@pirbright.ac.uk

KEOWN Jeremy, UNIVERSITY OF OXFORD, Oxford, United Kingdom - 14jeremy@strubi.ox.ac.uk

KERBER Romy, BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, Hamburg, Germany -P150 - kerber@bnitm.de

KIM Jin II, MICROBIOLOGY, KOREA UNIVERSITY COLLEGE OF MEDICINE, Seoul, Korea, Republic Of - airportblues@gmail.com

KIM Won-Keun, KOREA UNIVERSITY COLLEGE OF MEDICINE, Seoul, Korea, Republic Of - P227wkkim1061@korea.ac.kr

KLEINFELTER Lara, ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States - 6, P017lara.kleinfelter@phd.einstein.yu.edu

KLINGSTROM Jonas, KAROLINSKA INSTITUTET, Stockholm, Sweden - 41, P037jonas.klingstrom@ki.se

KOEHLER Alexander, PHILIPPS UNIVERSITY MARBURG, Marburg, Germany - P045alexander.koehler@staff.uni-marburg.de

KOHL Alain, MRC-UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH, Glasgow, United Kingdom - P042, P178alain.kohl@glasgow.ac.uk

KOJIMA Shohei, KYOTO UNIVERSITY, Kyoto, Japan - P044, P105, P237kojima.shohei.54u@st.kyoto-u.ac.jp

KOLAKOVSKY Daniel, Switzerlandpcomci@gmail.com

KONDOH Tatsunari, DIVISION OF GLOBAL EPIDEMIOLOGY, RESEARCH CENTER FOR ZOONOSIS CONTROL, HOKKAIDO UNIVERSITY, Sapporo, Japan - P010t.kondoh@czc.hokudai.ac.jp

KORMELINK Richard, WAGENINGEN UNIVERSITY, Wageningen, Netherlands - P046richard.kormelink@wur.nl

KORVA Misa, UNIVERSITY OF LJUBLJANA, FACULTY OF MEDICINE, INSTITUTE OF MICROBIOLOGY AND IMMUNOLOGY, Ljubljana, Slovenia - P150, P151misa.korva@mf.uni-lj.si

KOWALIK Timothy, UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL, Worcester, United StatesTimothy.Kowalik@umassmed.edu

KREHER Felix, GLASGOW UNIVERSITY, Glasgow, United Kingdom - P178felix.kreher@glasgow.ac.uk

KRÜGER Nadine, UNIVERSITY OF VETERINARY MEDICINE HANNOVER, Hannover, Germany -P015, P065, P127nadine.krueger@tiho-hannover.de

KRUMM Stefanie, KING'S COLLEGE LONDON, London, United Kingdom - 74, P191, P205stefanie.krumm@kcl.ac.uk

KUHN Jens, NIH/NIAID/DCR/INTEGRATED RESEARCH FACILITY AT FORT DETRICK, Frederick, United States – 84, P230kuhnjens@mail.nih.gov

KUMAR Gagandeep Renuka, CHAN ZUCKERBERG BIOHUB, San Francisco, United States -renuka.kumar@czbiohub.org

KUNZ Stefan, LAUSANNE UNIVERSITY HOSPITAL, Lausanne, Switzerland - 11, 85, P007, P008, P182Stefan.Kunz@chuv.ch

KUPKE Alexandra, INSTITUTE OF VIROLOGY, PHILIPPS UNIVERSITY MARBURG, Marburg, Germany - P176kupke@staff.uni-marburg.de

KUROSAKI Yohei, INSTITUTE OF TROPICAL MEDICINE, NAGASAKI UNIVERSITY, Nagasaki, Japan - P247ykuro@nagasaki-u.ac.jp

KUTTER Jasmin, ERASMUS MEDICAL CENTER ROTTERDAM, Rotterdam, Netherlandsj.kutter@erasmusmc.nl

KUWAHARA Tomoko, NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Musashi-Murayama, Japan - P177, P180kuwahara@nih.go.jp

LACOUNT Douglas, PURDUE UNIVERSITY, West Lafayette, United States - P126dlacount@purdue.edu

LAKDAWALA Seema, UNIVERSITY OF PITTSBURGH, Pittsburgh, United States - 52Lakdawala@pitt.edu

LAKSONO Brigitta, ERASMUS MC, Rotterdam, Netherlands - 60, P157b.laksono@erasmusmc.nl

LANGEDIJK Johannes, JANSSEN VACCINES AND PREVENTION, Leiden, Netherlands - 75, P200HLangedi@its.jnj.com

LANGLOIS Ryan, UNIVERSITY OF MINNESOTA, Minneapolis, United States - 42, 58ryan.a.langlois@gmail.com

LAPORTE Manon, REGA INSTITUTE - KU LEUVEN, Leuven, Belgium - P014, P217manon.laporte@kuleuven.be

LAU Simone, JUSTUS-LIEBIG UNIVERSITY, Giessen, Germany - P103Simone.Lau@vetmed.uni-giessen.de

LE GOFFIC Ronan, INRA, Jouy-En-Josas, France -P028, P040, P145, P152ronan.le-goffic@inra.fr

LEE Benhur, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States - P009, P021, P203benhur.lee@mssm.edu

LEE Sangjoon, UNIVERSITY OF TSUKUBA, Tsukuba, Japan - P060, P101s1335003@u.tsukuba.ac.jp

LEEMANS Annelies, UNIVERSITY OF ANTWERP, Wilrijk, Belgium - P173, P197annelies.leemans@uantwerpen.be

LENEVA Irina, FEDERAL STATE BUDGETARY SCIENTIFIC INSTITUTION I.MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA, Moscow, Russian Federation - P166wnyfd385@yandex.ru

LENOUEN Cyril, NIH/NIAID/LID, Bethesda, United States - 91, P185lenouenc@niaid.nih.gov

List of ParticipantsLEUNG Daisy, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE, St. Louis, United States -29dwleung@wustl.edu

LI Anzhong, THE OHIO STATE UNIVERSITY, Columbus, United States - 16, P195li.7875@osu.edu

LI Jianrong, THE OHIO STATE UNIVERSITY, Columbus, United States - 16, P195, P216li.926@osu.edu

LI Ping, Glasgow, United Kingdomping.li@glasgow.ac.uk

LIANG Bo, EMORY UNIVERSITY SCHOOL OF MEDICINE, Atlanta, United States - P029bo.liang@emory.edu

LIANG Mifang, NATIONAL INSTITUTE FOR VIRAL DISEASES CONTROL AND PREVENTION，CHINA CDC, Beijing, China - P221, P233mifangl@163.com

LIANG Xueya, DEPARTMENT OF VETERINARY BIOSCIENCES, COLLEGE OF VETERINARY MEDICINE, THE OHIO STATE UNIVERSITY, Dublin, United States - 16, P195, P216liang.135@osu.edu

LIEBERT Uwe G., LEIPZIG UNIVERSITY, Leipzig, Germany - P241liebert@medizin.uni-leipzig.de

LIU Cheng, ALIOS BIOPHARMA, INC., PART OF THE JANSSEN PHARMACEUTICAL COMPANIES, South San Francisco, United States -cliu114@its.jnj.com

LONG Jason, IMPERIAL COLLEGE LONDON, London, United Kingdom - 20jason.long08@imperial.ac.uk

LOWEN Anice, EMORY UNIVERSITY, Atlanta, United States - 21, 89anice.lowen@emory.edu

LUBAN Jeremy, UNIVERSITY OF MASSACHUSETTS MED SCHOOL, Worcester, United States - P001jeremy.luban@umassmed.edu

LUO Ming, GEORGIA STATE UNIVERSITY, Atlanta, United States - P024, P043mingvestavia@gmail.com

MAHAPATRA Madhuchhanda, THE PIRBRIGHT INSTITUTE, Woking, United Kingdom -mana.mahapatra@pirbright.ac.uk

MAISNER Andrea, PHILIPPS UNIVERSITY MARBURG, Marburg, Germany - P065, P110, P198, P238maisner@uni-marburg.de

MAKINO Akiko, KYOTO UNIVERSITY, Kyoto, Japan - 15, P105akkmakino@gmail.com

MANHART Whitney, BOSTON UNIVERSITY SCHOOL OF MEDICINE, Boston, United States -P102wmanhart@bu.edu

MANZOOR Rashid, RESEARCH CENTER FOR ZOONOSIS CONTROL, HOKKAIDO UNIVERSITY, Sapporo, Japan - P010, P184, P209manzoor@czc.hokudai.ac.jp

MARTÍNEZ-ROMERO Carles, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States - 30, P228carles.martinez@mssm.edu

MARTIN-SANCHO Laura, SBP MEDICAL DISCOVERY INSTITUTE, San Diego, United States - P068lmartin@sbpdiscovery.org

MASSIN Pascale, ANSES, Ploufragan, France -P154pascale.massin@anses.fr

MATEO Mathieu, INSTITUT PASTEUR, Lyon, France - 2, P097, P181mathieu.mateo@pasteur.fr

MATHIEU Cyrille, COLUMBIA UNIVERSITY MEDICAL CENTER, New York, United States - 61, 88cyrille.mathieu@inserm.fr

MATSUMOTO Yusuke, SCHOOL OF MEDICINE, WAKAYAMA MEDICAL UNIVERSITY, Wakayama, Japan - P094, P095ymatsu@wakayama-med.ac.jp

MAYOR Jennifer, LAUSANNE UNIVERSITY HOSPITAL, Lausanne, Switzerland - P007, P008, P182jennifer.mayor@unil.ch

MAZEL-SANCHEZ Béryl, UNIVERSITY OF GENEVA, Geneva, Switzerland - 36, P143beryl.mazel-sanchez@unige.ch

MAZUR Magdalena, LABORATORY OF VIROLOGY, WAGENINGEN UNIVERSITY, Wageningen, Netherlands - P046magdalena.mazur@wur.nl

MCMULLAN Laura, CENTERS FOR DISEASE CONTROL, Atlanta, United States - 40lim8@cdc.gov

MEDINA Rafael, PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE, Santiago, Chile - P108rmedinas@med.puc.cl

MEHLE Andrew, UNIVERSITY OF WISCONSIN MADISON, Madison, United States - 19amehle@wisc.edu

MEROUR Emilie, Jouy En Josas, France - 28emilie.merour@inra.fr

MERTZ Gregory, UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CETNERR, Albuquerque, United States -gmertz@salud.unm.edu

MEYER Léa, INRA, Jouy-En-Josas, France - P145lea.meyer@vet-alfort.fr

MIRAZIMI Ali, PUBLIC HEALTH AGENCY OF SWEDEN AND KAROLINSKA INSTITUTE, Stockholm, Sweden - P089Ali.Mirazimi@ki.se

MITTLER Eva, ALBERT EINSTEIN COLLEGE OF MEDICINE, New York, United States - 5, 6eva-maria.mittler@einstein.yu.edu

MIYAMOTO Sho, INSTITUTE FOR FRONTIER LIFE AND MEDICAL SCIENCES, KYOTO UNIVERSITY, Kyoto, Japan - P114miyamoto.sho.76w@st.kyoto-u.ac.jp

MOMOSE Fumitaka, KITASATO UNIVERSITY, Minato-Ku, Japan - P119fmomose@lisci.kitasato-u.ac.jp

MONCORGÉ Olivier, IRIM, Montpellier, France -37, P091olivier.moncorge@irim.cnrs.fr

MORENO BORREGO Hector, LAUSANNE UNIVERSITY HOSPITAL, Lausanne, Switzerland -85Hector.Moreno@chuv.ch

MORIYAMA Miyu, UNIVERSITY OF TOKYO, Tokyo, Japan - P080, P086, P162kk167333@stu-cbms.k.u-tokyo.ac.jp

MOSCONA Anne, COLUMBIA UNIVERSITY MEDICAL CENTER, New York, United States - 61, P175anm2047@gmail.com

MOTTET-OSMAN Geneviève, UNIVERSITY OF GENEVA, Geneva 4, Switzerlandgenevieve.mottet@unige.ch

MOTTRAM Timothy, MRC-UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH, Glasgow, United Kingdom - P042t.mottram.1@research.gla.ac.uk

List of ParticipantsMÜLLER Helena, PHILIPPS UNIVERSITY MARBURG, Marburg, Germany - P159muelle8t@students.uni-marburg.de

MUNIR Shirin, NATIONAL INSTITUTES OF HEALTH, Bethesda, United States -munirs@niaid.nih.gov

MUNOZ ALIA Miguel Angel, MAYO CLIIC, Rochester, United States - 78alia.miguel@mayo.edu

MUNOZ-FONTELA César Munoz-Fontela, BERNHARD-NOCHT INSTITUTE, Hamburg, Germany - P133, P146, P147, P150virusimmunology@bnitm.de

MUÑOZ-MORENO Raquel, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States - 30, P228raquel.munoz@mssm.edu

NAESENS Lieve, REGA INSTITUTE - KU LEUVEN, Leuven, Belgium - P014, P217lieve.naesens@kuleuven.be

NAKANO Masahiro, JAPAN/KYOTO UNIVERSITY, Kyoto, Japan - 45, P114nakanom@infront.kyoto-u.ac.jp

NAO Naganori, NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Musashimurayama City, Tokyo, Japan - P242n-nao@niid.go.jp

NEGRETE Oscar, SANDIA NATIONAL LABORATORIES, Livermore, United States - P212onegret@sandia.gov

NG Weng, DIVISION OF STRUCTURAL BIOLOGY, UNIVERSITY OF OXFORD, Oxford, United Kingdom - P018weng.ng@new.ox.ac.uk

NIETO Amelia, CENTRO NACIONAL DE BIOTECNOLOGIA-CSIC, Madrid, Spain - 33, 65anieto@cnb.csic.es

NISHIO Machiko, WAKAYAMA MEDICAL UNIVERSITY, Wakayama, Japan - P002, P094, P095mnishio@wakayama-med.ac.jp

NODA Takeshi, KYOTO UNIVERSITY, Kyoto, Japan - 45, P114t-noda@infront.kyoto-u.ac.jp

NOLDEN Tobias, VIRATHERAPEUTICS, Innsbruck, Austria - 49nolden@viratherapeutics.com

NORRIS Michael, THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States mnorris@scripps.edu

OESTEREICH Lisa, BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, Hamburg, Germany -P133, P146, P147, P150oestereich@bnitm.de

OHTA Keisuke, WAKAYAMA MEDICAL UNIVERSITY, Wakayama, Japan - P094, P095k-ooota@wakayama-med.ac.jp

OISHI Kohei, UNIVERSITY OF TOKYO, Minato-Ku, Japan - P0359335290098@edu.k.u-tokyo.ac.jp

OMAR Shadia, Newmarket, United Kingdom -P134omershadia@yahoo.co.uk

OUTLAW Victor, UNIVERSITY OF WISCONSIN–MADISON, Madison, United States - P175voutlaw@wisc.edu

OYMANS Judith, WAGENINGEN BIOVETERINARY RESEARCH, Utrecht, Netherlands - 57, 73Judith.Oymans@wur.nl

PALACIOS Gustavo, USAMRIID, Frederick, United States - 63, P070, P174, P227gustavo.palacios@gmail.com

PARIENTE Nonia, NATURE MICROBIOLOGY, London, United Kingdomnonia.pariente@nature.com

PARK Manseong, Seoul, Korea, Republic Of manseong.park@gmail.com

PARKER Lauren, MEDIMMUNE/ASTRAZENECA, Liverpool, United Kingdom - P187parkerla@medimmune.com

PARKINSON Nicholas, UNIVERSITY OF EDINBURGH, Roslin, United Kingdom -nick.parkinson@ed.ac.uk

PATTERSON Jean, San Antonio, United States -P012jpatters@txbiomed.org

PENG Kah-Whye, MAYO CLINIC, Rochester, United States - P031Peng.kah@mayo.edu

PERNET Olivier, UCLA, Los Angeles, United States - P203opernet@ucla.edu

PFAFFINGER Verena, GENE CENTER - MAX VON PETTENKOFER-INSTITUTE OF VIROLOGY, Munich, Germany - 27pfaffinger@genzentrum.lmu.de

PFALLER Christian, MAYO CLINIC, Rochester, United States - 2, 25, P067pfaller.christian@mayo.edu

PIETSCHMANN Thomas, TWINCORE, Hannover, Germany - 62, P020, P213thomas.pietschmann@twincore.de

PINTO Rute, THE ROSLIN INSTITUTE, THE UNIVERSITY OF EDINBURGH, Edinburgh, United Kingdom - P084s1564909@sms.ed.ac.uk

PLATTET Philippe, UNIVERSITY OF BERN, Bern, Switzerland - P011, P122, P123philippe.plattet@vetsuisse.unibe.ch

PÖHLMANN Stefan, GERMAN PRIMATE CENTER, Göttingen, Germany - P065, P093, P196spoehlmann@dpz.eu

POROTTO Matteo, COLUMBIA UNIVERSITY MEDICAL CENTER, Nw York, United States - 61, P175mporotto@gmail.com

PORT Julia, BERHARD NOCHT INSTITUT, Hamburg, Germany - P133, P147julia.port@bnitm.de

PRYCE Rhys, DIVISION OF STRUCTURAL BIOLOGY, UNIVERSITY OF OXFORD, Oxford, United Kingdom - P009, P018, P021rhys.pryce@new.ox.ac.uk

PULIT-PENALOZA Joanna, CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States - P136xzy5@cdc.gov

PUNCH Emma, 1989, London, United Kingdom -P022emmakpunch@gmail.com

RAMEIX-WELTI Marie-Anne, VERSAILLES SAINT QUENTIN UNIVERSITY, Montigny-Le-Bretonneux, France - P027, P039, P213marie-anne.rameix-welti@uvsq.fr

RANDALL Liz, UNIVERSITY OF ST ANDREWS, St Andrews, United Kingdom - 23liz.randall@btinternet.com

RANDALL Richard, UNIVERSITY OF ST ANDREWS, St Andrews, United Kingdom - 23, P072, P222rer@st-andrews.ac.uk

RANJAN Punya, CENTRE FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States - P210pranjan1@cdc.gov

RASMUSSEN Angela, COLUMBIA UNIVERSITY, New York, United States - P128alr2105@cumc.columbia.edu

READING Patrick, PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY, Melbourne, Australia - 38preading@unimelb.edu.au

REGUERA Juan, INSERM, Marseille, France - 12, P033reguera@afmb.univ-mrs.fr

RENNER Max, UNIVERSITY OF OXFORD, Oxford, United Kingdom - P034, P048maxrenner@strubi.ox.ac.uk

RENNICK MURPHY Linda, BOSTON UNIVERSITY, Boston, United States - 55, P049, P153rennick@bu.edu

REYNARD Stephanie, INSTITUT PASTEUR, Lyon, France - P138, P181stephanie.reynard@pasteur.fr

RICHARD Charles-Adrien, INRA, Jouy-En-Josas, France - P027, P039, P051, P055charles-adrien.richard@inra.fr

RICHARDSON Christopher, DALHOUSIE UNIVERSITY, Halifax, Canada - P169chris.richardson@dal.ca

RIMA Bert, QUEENS UNIVERSITY BELFAST, Belfast, United Kingdom - 61, P222b.rima@qub.ac.uk

RINGEL Marc, PHILIPPS-UNIVERSITY MARBURG, INSTITUTE OF VIROLOGY, Marburg, Germany -P110, P238marc.ringel@staff.uni-marburg.de

RISALVATO Jacquline, UNIVERSITY OF GEORGIA, Athens, United States - P043jcprisalvato@uga.edu

RISSANEN Ilona, UNIVERSITY OF HELSINKI, Helsinki, Finland - 10, P019, P248ilona.rissanen@helsinki.fi

ROGERS Kai, UNIVERSITY OF IOWA, Iowa City, United States - P079kai-rogers@uiowa.edu

ROHDE Cornelius, INSTITUTE OF VIROLOGY, PHILIPPS-UNIVERSITY MARBURG, Marburg, Germany - 31, P047Rohdecor@staff.uni-marburg.de

ROSENTHAL Maria, BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE, Hamburg, Germany - P033rosenthal@bnitm.de

ROTHENBERGER Sylvia, LAUSANNE UNIVERSITY HOSPITAL, Lausanne, Switzerland - P007, P008, P182Sylvia.Rothenberger-Aubert@chuv.ch

ROTTSTEGGE Monika, BERNHARD-NOCHT-INSTITUTE, Hamburg, Germany - P146rottstegge@bnitm.de

ROUX Laurent, UNIVERSITY OF GENEVA, Geneva 4, Switzerlandlaurent.roux@unige.ch

ROUXEL Ronan, GSK, Rixensart, Belgium - P199ronan.n.rouxel@gsk.com

ROYMANS Dirk, JANSSEN PHARMACEUTICA NV, Beerse, Belgium - 75, P200droymans@its.jnj.com

RUBIN Steven, FDA, Silver Spring, United States -P153steven.rubin@fda.hhs.gov

RUIGROK Rob, IBS, Grenoble, France - 44, P026, P040rob.ruigrok@ibs.fr

RUSSELL Charles, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, MEMPHIS, TN, Memphis, United States - 53charles.russell@stjude.org

SAKABE Saori, THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States - P088ssakabe@scripps.edu

SATO Hiroki, INSTITUTE OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO, Tokyo, Japan - P053, P090, P096, P124, P137, P139satohi@ims.u-tokyo.ac.jp

SCHAEFFER Justine, INSTITUT PASTEUR, Lyon, France - P138, P181justine.schaeffer@pasteur.fr

SCHIERHORN Kristina, KING'S COLLEGE LONDON, London, United Kingdom - 39, P075kristina.schierhorn@kcl.ac.uk

SCHLOTTAU Kore, FRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Riems, Germany - P202kore.schlottau@fli.de

SCHMALJOHN Connie, US ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES, Frederick, United States - P140, P161, P243connie.s.schmaljohn.civ@mail.mil

SCHMOLKE Mirco, UNIVERSITY OF GENEVA, Geneve, Switzerland - 36, P143, P206mirco.schmolke@unige.ch

SCHNEPF Daniel, MEDICAL CENTER UNIVERSITY OF FREIBURG, Freiburg Im Breisgau, Germany -56, P193daniel.schnepf@uniklinik-freiburg.de

SCHOEPP Randal, USAMRIID, Fort Detrick, United States - P223, P243randal.schoepp@gmail.com

SCHOLTE Florine, CDC, Atlanta, United States -40, P131, P132kyj7@cdc.gov

SCHOUNTZ Tony, COLORADO STATE UNIVERSITY, Fort Collins, United States - 90, P224tony.schountz@colostate.edu

SCHRAMM Antoine, AFMB CNRS, Marseille, France - P038, P058antoine.schramm@afmb.univ-mrs.fr

SCHRAUF Sabrina, THEMIS BIOSCIENCE GMBH, Vienna, Austriasabrina.schrauf@themisbio.com

SCHULTZ-CHERRY Stacey, ST JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, United States -54stacey.schultz-cherry@stjude.org

SCHULZ Helene, PUBLIC HEALTH AGENCY OF CANADA, Winnipeg, Canada - P232Helene.Schulz@canada.ca

SCHULZE Jessica, ROBERT KOCH INSTITUTE, Berlin, Germany - 67schulzej@rki.de

SCHWEMMLE Martin, UNIVIVERSITY FREIBURG, Freiburg, Germany - 1, 19, 90, P196martin.schwemmle@uniklinik-freiburg.de

SELVARAJ Muneeswaran, THE PIRBRIGHT INSTITUTE, Woking, United Kingdom - P158muni.selvaraj@pirbright.ac.uk

SERNA MARTIN Itziar, UNIVERSITY OF OXFORD, Oxford, United Kingdom - 14, P034itziar.sernamartin@path.ox.ac.uk

SHCHERBIK Svetlana, CDC/NCRID, Atlanta, United States - P207wit7@cdc.gov

SHI Xiaohong, UNIVERSITY OF GLASGOW, Glasgow, United Kingdomxiaohong.shi@glasgow.ac.uk

SHU Bo, CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States - P245, P246brs9@cdc.gov

SILVIA Ashley, TEXAS BIOMEDICAL RESEARCH INSTITUTE, San Antonio, United States - P054asilvia@txbiomed.org

SLAINE Patrick, DALHOUSIE UNIVERSITY, Ridgeville, Canada - P155patrick.slaine@dal.ca

SLOAN Elizabeth, CVR-UNIVERSITY OF GLASGOW, Glasgow, United Kingdom - 43, P032elizabeth.sloan@glasgow.ac.uk

SLOUGH Megan, ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States - 6, P006slough@mail.einstein.yu.edu

SOETENS Eline, VIB/UGENT, Anzegem, Belgium -P104eline.soetens@vib-ugent.be

SOLÀ RIERA Carles, KAROLINSKA INSTITUTET, Stockholm, Sweden - 41carles.sola.riera@ki.se

SONG Jin Won, KOREA UNIVERSITY COLLEGE OF MEDICINE, Seoul, Korea, Republic Of - P227jwsong@korea.ac.kr

SPIROPOULOU Christina, Atlanta, United States - 40, P049, P131, P132, P172, P210ccs8@cdc.gov

SPRONKEN Monique, ERASMUS MEDICAL CENTRE, Rotterdam, Netherlands - P041m.spronken@erasmusmc.nl

STAEHELI Peter, UNIVERSITY OF FREIBURG, GERMANY, Freiburg, Germany - 56, P060, P193peter.staeheli@uniklinik-freiburg.de

STASS Robert, STRUBI, UNIVERSITY OF OXFORD, Oxford, United Kingdom - 10, P019robertstass@strubi.ox.ac.uk

STEEL John, EMORY UNIVERSITY, Atlanta, United States - 21, 89john.steel@emory.edu

STELFOX Alice, UNIVERSITY OF OXFORD, Oxford, United Kingdom - P218, P248alice.stelfox@pmb.ox.ac.uk

STERTZ Silke, UNIVERSITY OF ZURICH, Zurich, Switzerland - 1stertz.silke@virology.uzh.ch

STEVAERT Annelies, REGA INSTITUTE - KU LEUVEN, Leuven, Belgium - P014, P217annelies.stevaert@kuleuven.be

STRECKER Thomas, Marburg, Germany - P118, P159, P215strecker@staff.uni-marburg.de

SUBBARAO Kanta, THE PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY, Melbourne, Australia - 76kanta.subbarao@influenzacentre.org

SUGAI Akihiro, THE UNIVERSITY OF TOKYO, Tokyo, Japan - P053, P124, P137sugai@ims.u-tokyo.ac.jp

SUKHIASHVILI Roena, NATIONAL CENTER FOR DISEASE CONTROL AND PUBLIC HEALTH (NCDC), Tbilisi, Georgia - P234, P243r.sukhiashvili@ncdc.ge

SZEMIEL Agnieszka, MRC - UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH, Glasgow, United Kingdom - P074agnieszka.szemiel@glasgow.ac.uk

TAHARA Maino, NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Musashimurayama, Japan - 92maino@nih.go.jp

TAKADA Ayato, HOKKAIDO UNIVERSITY, Sapporo, Japan - P010, P184, P209, P240atakada@czc.hokudai.ac.jp

TAKAHASHI Hitoshi, NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Musashimurayama, Japan - P177, P208takajin@nih.go.jp

TAKAMATSU Yuki, INSTITUTE OF VIROLOGY, PHILIPPS UNIVERSITY MARBURG, Marburg, Germany - P036yuki.takamatsu@staff.uni-marburg.de

TAKASHITA Emi, NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Tokyo, Japan - P177, P180emitaka@nih.go.jp

TAKEDA Makoto, NATIONAL INSTITUTE OF INFECTIOUS DISEASES, Musashimurayama, Japan - 92, P242mtakeda@nih.go.jp

TAKIMOTO Toru, UNIVERSITY OF ROCHESTER MEDICAL CENTER, Rochester, United States -P063toru_takimoto@urmc.rochester.edu

TAKIZAWA Naoki, INSTITUTE OF MICROBIAL CHEMISTRY (BIKAKEN), Tokyo, Japan - 51takizawan@bikaken.or.jp

TAMHANKAR Manasi Ajit, TEXAS BIOMEDICAL RESEARCH INSTITUTE, San Antonio, United States - P012mtamhankar@txbiomed.org

TE KAMP Verena, FRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany -49verena.tekamp@fli.de

TE VELTHUIS Aartjan, UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom - 66, 71ajwt6@cam.ac.uk

TENG Michael, UNIVERSITY OF SOUTH FLORIDA, Tampa, United States - P170mteng@health.usf.edu

TENOEVER Benjamin, ICAHN SCHOOL OF MEDICINE, New York, United States - 30, 93, P078Benjamin.tenOever@mssm.edu

THAMAMONGODD Thiprampai, INSTITUTE OF VIROLOGY, MEDICAL CENTER UNIVERSITY FREIBURG, Freiburg, Germany - 1, 19thiprampai@gmail.com

TILSTON-LUNEL Natasha, BOSTON UNIVERISTY, Boston, United States - 55, P049ntilston@bu.edu

TISCHLER Nicole, FUNDACIÓN CIENCIA PARA LA VIDA, Santiago, Chile - 6, 9, P007, P008, P149, P182ntischler@cienciavida.org

TOMONAGA Keizo, KYOTO UNIVERSITY, Kyoto, Japan - 15, P044, P098, P105, P237tomonaga@infront.kyoto-u.ac.jp

TONG Suxiang, CDC, Atlanta, United States -P235sot1@cdc.gov

TORRIANI Giluia, LAUSANNE UNIVERSITY HOSPITAL, Lausanne, Switzerland - 11, P007, P008, P182Giulia.Torriani@chuv.ch

TOWNER Jonathan, Atlanta, United States - 63, P070jit8@cdc.gov

TRIPATHI Shashank, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States - P068, P069shashank.tripathi@mssm.edu

TSURUDOME Masato, CHUBU UNIVERSITY, Kasugai, Japan - P002, P094crane1629@yahoo.co.jp

TYNELL Janne, KAROLINSKA INSTITUTET, Stockholm, Sweden - P037janne.tynell@ki.se

UCHIDA Shotaro, JAPAN, Tokyo, Japan - P090, P139, P211uchida-s@ims.u-tokyo.ac.jp

UEKI Hiroshi, INSTITUTE OF MEDICAL SCIENCE, UNIVERSITY OF TOKYO, Tokyo, Japan - 68h-ueki@ims.u-tokyo.ac.jp

ULRICH Rainer, FRIEDRICH-LOEFFLER-INSTITUT, Greifswald-Insel Riems, Germany - P236rainer.ulrich@fli.de

URATA Shuzo, NAGASAKI UNIVERSITY, INSTITUTE OF TROPICAL MEDICINE, Nagasaki, Japan - 72, P118shuzourata@nagasaki-u.ac.jp

VAN KNIPPENBERG Ingeborg, UNIVERSITY OF GLASGOW, Glasgow, United Kingdom - P032ingeborg.vanknippenberg@glasgow.ac.uk

VERA OTAROLA Jorge, LABORATORIO DE VIROLOGÍA MOLECULAR, INSTITUTO MILENIO DE INMUNOLOGÍA E INMUNOTERAPIA, CENTRO DE INVESTIGACIONES MÉDICAS, DEPARTAMENTO DE ENFERMEDADES INFECCIOSAS E INMUNOLOGÍA PEDIÁTRICA , ESCUELA DE MEDICINA, PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE., Santiago, Chile - P100javochile@gmail.com

VOLCHKOV Viktor, CIRI INSERM 1111, Lyon, France - P097viktor.volchkov@inserm.fr

VOLCHKOVA Valentina, CIRI 1111, Lyon, France -P097valentina.volchkova@inserm.fr

VON MESSLING Veronika, PAUL-EHRLICH-INSTITUT, Langen, Germany - 69veronika.vonmessling@pei.de

VON RECUM Jessica, JANSSEN PHARMACEUTICA NV, Beerse, Belgiumjvrecum@its.jnj.com

WALKER Alex, UNIVERSITY OF OXFORD, Cirencester, United Kingdom - P056alexander.walker@path.ox.ac.uk

WARREN Travis, US ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES, Frederick, United States - 70travis.k.warren@gmail.com

WATANABE Yasunori, UNIVERSITY OF SOUTHAMPTON, Oxford, United Kingdom -P215, P218yasunori.watanabe@spc.ox.ac.uk

WATANABE Yohei, KYOTO PREFECTURAL UNIVERSITY OF MEDICINE, Kyoto, Japan - P226, P244nabe@koto.kpu-m.ac.jp

WATKINSON Ruth, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, United States -P203ruth.watkinson@mssm.edu

WEARY Taylor, TEXAS BIOMEDICAL RESEARCH INSTITUTE, San Antonio, United States - 59tweary@txbiomed.org

WEBER Friedemann, JUSTUS LIEBIG UNIVERSITY GIESSEN, INSTITUTE FOR VIROLOGY FB10, Giessen, Germany - P083, P089, P103friedemann.weber@vetmed.uni-giessen.de

WELCH Stephen, CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States - 40, P049, P132, P172yos6@cdc.gov

WENTWORTH David, CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States - 80, P164, P207, P245, P246dwentworth@cdc.gov

WHELAN Sean, HARVARD MEDICAL SCHOOL, Boston, United States - 13, 24, P016, P050, P179SPJWHELAN@GMAIL.COM

WICHGERS SCHREUR Paul, WAGENINGEN BIOVETERINARY RESEARCH, Lelystad, Netherlands - 57, 73paul.wichgersschreur@wur.nl

WIECHERT Svenja, TWINCORE, CENTRE FOR EXPERIMENTAL AND CLINICAL INFECTION RESEARCH, Hannover, Germany - P020, P213svenja.wiechert@twincore.de

WIGNALL-FLEMING Elizabeth, UNIVERSITY OF ST ANDREWS, St Andrews, Fife, United Kingdom -23, P222E0606137w@hotmail.co.uk

WILLIAMS Evan, UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER, Memphis, United States - P085ewilli99@uthsc.edu

WU Kai-Hui, CENTERS FOR DISEASE CONTROL AND PREVENTION, Atlanta, United States - P245, P246ckq8@cdc.gov

WUERTH Jennifer, JUSTUS-LIEBIG UNIVERSITY GIESSEN, Giessen, Germany - P083jennifer.wuerth@vetmed.uni-giessen.de

XUE Miaoge, THE OHIO STATE UNIVERSITY, Columbus, United States - 16, P195, P216xue.303@osu.edu

YAHIRO Mukai, INSTITUTE FOR FRONTIER LIFE AND MEDICAL SCIENCES , KYOTO UNIVERSITY, Kyoto, Japan - 87mukai.yahiro.24s@st.kyoto-u.ac.jp

YAMAYOSHI Seiya, INSTITUTE OF MEDICAL SCIENCE, UNIVERSITY OF TOKYO, Tokyo, Japan -77, P035, P135yamayo@ims.u-tokyo.ac.jp

YANAI Mako, KYOTO UNIVERSITY, Kyoto, Japan -P044, P105yanai.mako.24z@st.kyoto-u.ac.jp

YANG Patrick (Genyan), CDC, Atlanta, United States gyang@cdc.gov

YASUDA Jiro, NAGASAKI UNIVERSITY, Nagasaki, Japan - 72, P077, P118, P247j-yasuda@nagasaki-u.ac.jp

YASUHARA Atsuhiro, INSTITUTE OF MEDICAL SCIENCE, UNIVERSITY OF TOKYO, JAPAN, Tokyo, Japan - 77, P1354991100194@edu.k.u-tokyo.ac.jp

YE Liang, INSTITUTE OF VIROLOGY, MEDICAL CENTER UNIVERSITY OF FREIBURG, Freiburg, Germany - 56, P193liang.ye@uniklinik-freiburg.de

YILDIZ Soner, UNIVERSITY OF GENEVA, CMU, Geneva, Switzerland - P143soner.yildiz@unige.ch

YONEDA Misako, THE UNIVERSITY OF TOKYO, Tokyo, Japan - P053, P090, P096, P124, P137, P139, P211yone@ims.u-tokyo.ac.jp

YOSHIDA Asuka, THE INSTITUTE OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO, Tokyo, Japan - P090, P120ayoshida@ims.u-tokyo.ac.jp

YOSHIDA Reiko, HOKKAIDO UNIVERSITY, Sapporo, Japan - P010, P209ryoshida@czc.hokudai.ac.jp

YOSHIKAWA Rokusuke, NAGASAKI UNIVERSITY, Nagasaki-Shi, Japan - P077kyusyu.sinden@gmail.com

ZAECK Luca, FRIEDRICH-LOEFFLER-INSTITUT, Greifswald - Insel Riems, Germany - 49, P156luca.zaeck@fli.de

ZAHN Roland, JANSSEN VACCINES & PREVENTION, Leiden, Netherlands - P189rzahn@its.jnj.com

ZHOU Yan, UNIVERSITY OF SASKATCHEWAN, Saskatoon, Canada - P062yan.zhou@usask.ca

ZIEGLER Christopher, UNIVERSITY OF VERMONT, Burlington, United States - 47, 48, P112cziegler@uvm.edu

ZIMMER Gert, INSTITUTE OF VIROLOGY AND IMMUNOLOGY (IVI), Mittelhäusern, Switzerland - 11, P005, P007, P008, P182, P231gert.zimmer@ivi.admin.ch

ZUEST Roland, SPIEZ LABORATORY, Spiez, Switzerland -roland.zuest@babs.admin.ch

to do list …

to be continued …

… see you all again for #NSV2021 …

where would you go …?

Back cover image courtesy of Seema Lakdawala, University of Pittsburgh, USA

www.negativestrandvirus.org

info@negativestrandvirus.org

powerpoint presentation nsv 2018 070618 v3.pdf · nsv 2013: palacio de congresos, granada, spain...

Documents

siena 20.5.2013

eesti nsv riikliku julgeoleku komitee records (hoover...

070618 110706051724-phpapp01

bloederig treffen nsv en krakers

prueba siena

posledni zabeleski po nsv

controversieel nsv!-congres moet uitwijken naar antwerpen

siena - conexÕes

painel siena

siena, 1941 - salcis | siena

102 /a siena - pievasciata - ponte di pianella · siena...

mu kodu - nsv liit

siena locandina

sightseeing siena: stadtführungen & tickets - viva...

siena bando

narvajÕe lademe geoloogiast eesti nsv s

siena presentation

eesti vabariigi ja nsv liidu vaheline …€¦ · eesti...

anti-nsv betoging. waarom deelnemen?

sonicwall...web application firewall cas cloud app security...